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ABSTRACT 
Triplex-forming oligonucleotides (TFOs) have received considerable interest 
because of their ability to recognize double-helical DNA and RNA sequence-
selectively. Sequence-selective binding to double-helical DNA would enable 
controlling the function of a certain gene through triplex formation, which makes 
TFOs potential therapeutic agents. In recent years, the recognition of double-helical 
RNA through triplex formation has attracted increasing interest because of the 
central role of noncoding, double-helical RNA in cellular processes and gene 
expression. With TFO-based recognition, it would be possible to detect these 
double-helical RNA molecules and interfere with their function. However, 
unmodified TFOs have certain limitations such as poor triplex stability at 
physiological pH and poor cellular delivery. To overcome these limitations, various 
chemical modifications have been introduced into TFOs. 
In the present thesis, TFOs and triplex-forming peptide nucleic acids 
(TFPNAs) were modified to increase their affinity for DNA and RNA duplexes. 
The binding affinity for DNA duplexes could be increased by conjugating TFOs 
with neomycin, a known groove binder. Moreover, the importance of the 
conjugation site was demonstrated. The binding affinity and specificity of TFPNAs 
for RNA duplexes could be increased by introducing chiral backbone 
modifications. TFPNAs with an appropriate pattern of γ-(R)-hydroxymethyl and γ-
(S)-guanidinylmethyl modifications preferred stoichiometric Hoogsteen-face 
binding to a microRNA-215 model, and the γ-(S)-guanidinylmethyl modifications 
also enhanced the cellular uptake of TFPNAs. Additionally, 19F-labeled RNA 
target hairpins and 19F NMR spectroscopy were used to reveal detailed information 
on the stoichiometry and transition between alternative binding modes, 
stoichiometric PNA/RNA triplex and ternary (PNA)2/RNA triplex invasion 
complex. Furthermore, this thesis describes 19F-labeled TFO probes able to 
recognize variable nucleobases in the pyrimidine strand of double-helical DNA. 
KEY WORDS: triplex-forming oligonucleotides, peptide nucleic acids, 19F NMR 
spectroscopy, DNA, RNA  
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TIIVISTELMÄ 
Kolmoisjuosteen muodostavat oligonukleotidit (TFOt) ovat herättäneet suurta 
mielenkiintoa, sillä ne pystyvät sitoutumaan kaksijuosteiseen DNA:han ja 
RNA:han sekvenssiselektiivisesti. Tämän ominaisuutensa ansiosta TFO-juosteilla 
on sovelluskohteita esimerkiksi uudenlaisina diagnostisina koettimina ja ne ovat 
myös potentiaalisia lääkeaineita. Sekvenssiselektiivinen sitoutuminen kaksi-
juosteiseen DNA:han voisi mahdollistaa haluttujen geenien toiminnan 
säätelemisen. Myös kaksijuosteisella, ei-koodaavalla RNA:lla on merkittävä rooli 
geenien ilmenemisessä. TFO-juosteiden avulla näitä kaksijuosteisia RNA-
molekyylejä voitaisiin havaita ja niiden toimintaan voitaisiin vaikuttaa. TFO-
juosteiden käyttökelpoisuutta rajoittavat kuitenkin esimerkiksi kolmoisjuosteen 
heikko pysyvyys fysiologisessa pH:ssa ja heikko kulkeutuminen soluun.  
Tässä väitöskirjatyössä TFO-juosteita ja kolmoisjuosteen muodostavia 
peptidinukleiinihappoja (TFPNAt) muokattiin kemiallisesti, jotta niiden sitoutu-
misvoimakkuus DNA- ja RNA-kaksoisjuosteisiin kasvaisi. Sitoutumisvoimak-
kuutta DNA-kaksoisjuosteisiin saatiin kasvatettua liittämällä TFO-juosteisiin 
neomysiiniä, joka pystyy sitoutumaan kolmoisjuosteen isoon uurteeseen. TFPNA-
juosteiden sitoutumisvoimakkuutta ja -spesifisyyttä taas saatiin kasvatettua 
kiraalisilla TFPNA-rakenteilla. TFPNAt, joiden sopiviin kohtiin oli liitetty γ-(R)-
hydroksimetyyli- tai γ-(S)-guanidinyylimetyyliryhmiä, suosivat stoikiometristä, 
Hoogsteen-vetysidoksiin perustuvaa sitoutumista mikroRNA-215-malliin. γ-(S)-
guanidinyylimetyyliryhmät myös paransivat TFPNA-juosteiden kulkeutumista 
soluun. Lisäksi 19F-leimattujen RNA-kaksoisjuosteiden ja 19F-NMR-
spektroskopian avulla paljastui yksityiskohtaista tietoa TFPNA-juosteiden 
vaihtoehtoisista sitoutumismekanismeista. Lisäksi tässä väitöskirjatyössä kehitettiin 
19F-leimattuja TFO-koettimia, joiden avulla pystyttiin tunnistamaan yksittäisiä 
nukleoemäksiä DNA-kaksoisjuosteen pyrimidiinijuosteessa. 
AVAINSANAT: kolmoisjuosteen muodostava oligonukleotidi, 
peptidinukleiinihappo, 19F-NMR-spektroskopia, DNA, RNA 
 
  5 
Contents 
List of Original Publications ........................................................... 7 
List of Related Publications ........................................................... 8 
Abbreviations and Symbols ........................................................... 9 
1 Introduction ............................................................................. 12 
1.1 DNA triplexes ......................................................................... 13 
1.1.1 Improving the binding properties and cellular delivery 
of TFOs …………... ..................................................... 15 
1.1.1.1 Nucleobase modifications ............................. 16 
1.1.1.2 Sugar modifications ...................................... 17 
1.1.1.3 Backbone modifications ................................ 18 
1.1.1.4 Triplex-stabilizing ligands .............................. 20 
1.1.1.5 Improving the cellular delivery of TFOs ......... 22 
1.1.2 Potential applications of TFOs ..................................... 24 
1.1.2.1 Modulating transcription and replication via 
triplex formation ............................................ 24 
1.1.2.2 Introducing or correcting mutations site-
specifically .................................................... 25 
1.1.2.3 Tools for biotechnology and 
nanotechnology ............................................ 25 
1.1.2.4 Recognition of the nucleobase content in 
the target DNA duplex by TFO probes .......... 26 
1.2 RNA triplexes ......................................................................... 27 
1.2.1 Recognition of double-helical RNA by triplex-forming 
peptide nucleic acids (TFPNAs) .................................. 28 
1.2.1.1 Nucleobase modifications ............................. 29 
1.2.1.2 PNA backbone modifications ........................ 30 
1.2.2 Potential applications .................................................. 31 
1.3 Methods for investigating triplexes ......................................... 33 
1.3.1 Conventional methods ................................................. 33 
1.3.2 19F NMR spectroscopy ................................................ 33 
2 Aims of the Thesis .................................................................. 36 
3 Results and Discussion ......................................................... 38 
3.1 DNA triplex stabilization by neomycin-conjugated TFOs ........ 38 
3.1.1 Synthesis of C-5, C-2’ and C-4’-neomycin-conjugated 
TFOs ….. .................................................................... 39 
3.1.1.1 Building blocks 1–4 ....................................... 39 
  6 
3.1.1.2 Oligonucleotide synthesis .............................. 40 
3.1.2 UV thermal melting studies .......................................... 41 
3.1.3 19F NMR studies ........................................................... 45 
3.2 Recognition of the nucleobase content in the target DNA 
duplex by 19F-labeled TFO probes .......................................... 48 
3.2.1 Synthesis of the 19F-labeled TFO probes ..................... 50 
3.2.1.1 Synthesis of the Phosphoramidite Building 
Blocks of Sensors F2 and F3 ......................... 50 
3.2.1.2 Oligonucleotide synthesis .............................. 50 
3.2.2 UV thermal melting studies .......................................... 51 
3.2.3 19F NMR studies ........................................................... 52 
3.3 Recognition of double-helical microRNA by TFPNAs .............. 57 
3.3.1 Synthesis of PNAs ....................................................... 58 
3.3.1.1 PNA monomers ............................................. 58 
3.3.1.2 Synthesis of TFPNAs and ORNs ................... 61 
3.3.2 19F NMR spectroscopic analysis of PNA/RNA 
triplexes .. .................................................................... 62 
3.3.2.1 PNA/heg hairpin triplexes .............................. 62 
3.3.2.2 PNA/miR-215 triplexes .................................. 67 
3.3.2.2.1 γ-(S)-guanidinylmethyl-modified 
TFPNAs ........................................ 74 
3.3.3 UV and CD spectroscopic analysis of PNA/RNA 
triplexes .. .................................................................... 78 
3.3.4 Cellular uptake studies of TFPNAs ............................... 82 
4 Summary .................................................................................. 85 
5 Experimental ............................................................................ 88 
5.1 General ................................................................................... 88 
5.2 Oligonucleotide synthesis ....................................................... 88 
5.3 PNA synthesis ........................................................................ 88 
5.3.1 Synthesis of guanidine-modified PNAs 7–9 and 
HF488-PNAs 7–9 ........................................................ 89 
5.4 UV and CD thermal melting studies ........................................ 90 
5.5 19F NMR studies ...................................................................... 90 
Acknowledgements ....................................................................... 91 
References ...................................................................................... 93 
Original Publications ................................................................... 103 
 
  7 
List of Original Publications 
The thesis is based on the following publications: 
I Tähtinen, V., Granqvist, L. and Virta, P.: Synthesis of C-5, C-2’ and C-4’-
neomycin-conjugated triplex forming oligonucleotides and their affinity to 
DNA-duplexes. Bioorg. Med. Chem. 2015, 23, 4472–4480. 
II Tähtinen, V., Granqvist, L., Murtola, M., Strömberg, R. and Virta, P.: 19F NMR 
spectroscopic analysis of the binding modes in triple-helical peptide nucleic 
acid (PNA)/microRNA Complexes. Chem. Eur. J. 2017, 23, 7113–7124. 
III Bhuma, N., Tähtinen, V. and Virta, P.: Synthesis and applicability of base-
discriminating DNA-triplex-forming 19F NMR probes. Eur. J. Org. Chem. 
2018, 2018, 605–613. 
IV Tähtinen, V., Verhassel, A., Tuomela, J. and Virta, P.: γ-(S)-Guanidinylmethyl 
Modified Triplex-Forming Peptide Nucleic Acids Increase Hoogsteen-Face 
Affinity for a MicroRNA and Enhance Cellular Uptake. (accepted manuscript) 
ChemBioChem 10.1002/cbic.201900393 
The original publications have been reproduced with permission of the copyright 
holders. Article I: Copyright (2015) Elsevier Ltd; Article II: Copyright (2017) Wiley-
VCH Verlag GmbH & Co. KGaA, Weinheim; Article III: Copyright (2018) Wiley-
VCH Verlag GmbH & Co. KGaA, Weinheim. 
  
  8 
List of Related Publications 
Granqvist, L., Kraszewski, A., Tähtinen, V. and Virta, P.: Synthesis of 
aminoglycoside-2′-O-methyl oligoribonucleotide fusions. Molecules 2017, 22, 
760–772. 
Granqvist, L., Tähtinen, V. and Virta, P.: Synthesis of Glycosidic (β-1’’→6, 3’ and 
4’) Site Isomers of Neomycin B and their Effect on RNA and DNA Triplex 
Stability. Molecules 2019, 24, 580–591. 
 
  9 
Abbreviations and Symbols 
A adenine 
Ac acetyl 
AE aminoethylribose 
AEEA 2-(2-aminoethoxy)ethoxy acetic acid 
All allyl 
Arg arginine 
2’,4’-BNANC 2’-O,4’-C-aminomethylene bridged nucleic acid 
Boc tert-butyloxycarbonyl 
BOP (benzotriazol-1-yloxy)tris(dimethylamino)phosphonium 
hexafluorophosphate 
BQQ benzo[f]quino[3,4-b]quinoxaline 
C cytosine 
CD circular dichroism 
dA  2’-deoxyadenosine 
DCM dichloromethane 
DIEA N,N-diisopropylethylamine 
DMF dimethylformamide 
DMSO dimethyl sulfoxide 
DMTr 4,4′-dimethoxytrityl 
DNA deoxyribonucleic acid 
ds double-stranded 
dT 2’-deoxythymidine 
dU 2’-deoxyuridine 
ENA ethylene-bridged nucleic acid 
Et3N triethylamine 
ESI-TOF MS electrospray ionization time-of-flight mass spectrometry 
Fmoc fluorenylmethyloxycarbonyl 
G guanine 
GAL4 galectin-4 protein 
GPNA guanidine-modified PNA 
H-DNA  naturally occurring triple-helical DNA 
heg hexaethylene glycol 
  10 
HF488 HiLyte Fluor 488 
HIV human immunodeficiency virus 
HIV-TAR human immunodeficiency virus trans-activation response element 
HPLC high performance liquid chromatography 
HRMS high resolution mass spectrometry 
iC 5-methylisocytosine 
ITC isothermal titration calorimetry 
LCAA-CPG long chain alkylamine controlled pore glass 
LNA locked nucleic acid 
lncRNA long noncoding RNA 
Lys lysine 
Me methyl 
MeC 5-methylcytosine 
MEG3 maternally expressed gene 3 
Me3P trimethylphosphine 
Me3SiCl trimethylsilyl chloride 
MeP 3-methyl-2-aminopyridine 
miRNA microRNA 
miR-215 microRNA-215 
mRNA messenger RNA 
NER nucleotide excision repair 
NIS N-iodosuccinimide 
NMP N-methyl-2-pyrrolidone 
NMR nuclear macnetic resonance 
ODN 2’-deoxyoligonucleotide 
ON oligonucleotide 
ORN oligoribonucleotide 
Pbf 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl 
PMB p-methoxybenzyl 
PNA peptide nucleic acid 
PNHDMAP dimethylaminopropyl phosphoramidate 
–1 PRF –1 programmed ribosomal frameshifting 
PS phosphorothioate  
PvuII a restriction enzyme from Proteus vulgaris 
Py pyridine 
PyBOP benzotriazol-1-yl-oxytripyrrolidinophosphonium 
hexafluorophosphate 
rA adenosine 
RNA ribonucleic acid 
RP-HPLC reverse-phase high performance liquid chromatography 
rt room temperature 
  11 
rU uridine 
SNP single-nucleotide polymorphism 
ss single strand 
T thymine 
TBTA tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine 
tBu tert-butyl 
TFA trifluoroacetic acid 
Tfa trifluoroacetyl 
TFO triplex-forming oligonucleotide 
TFPNA triplex-forming peptide nucleic acid 
TGF-β transforming growth factor beta 
THF tetrahydrofurane 
Tm thermal melting temperature 
Tm3 triplex thermal melting temperature 
TMS trimethylsilyl ether 
Trt trityl 
TTS triple-helix target sequence 
U uracil 
UV ultraviolet 
VP16 Herpes simplex virus protein 16 
  12 
1 Introduction 
Triplex-forming oligonucleotides (TFOs) have received considerable interest because 
of their potential as therapeutic agents that sequence-selectively recognize double-
helical DNA.1,2 The sequence of the DNA base pairs in double-helical DNA holds the 
genetic information and gives the cell the instructions to perform its functions. The 
double-helical structure of DNA was discovered in 1953.3–5 Four years later, 
Felsenfeld et al. reported the formation of a three-stranded structure between one 
poly(rA) and two poly(rU) chains in the presence of Mg2+.6 However, it took 30 years 
until researchers started to realize that genes and their function could be modulated by 
TFOs that bind sequence-specifically to the major groove of DNA duplexes. In 1987, 
short oligonucleotides were used to direct DNA double helix cleavage sequence-
specifically through triplex formation.7,8 At the time, the potential of TFOs in the 
control of gene expression was also suggested.9,10 To date, the ability of TFOs to 
control gene expression site-specifically has been demonstrated in numerous 
studies.1,2,11–13 For instance, TFOs have been shown to inhibit transcription and 
replication and to induce site-directed mutations, recombination and DNA repair. 
Furthermore, TFOs have been used to target cleaving and cross-linking agents, 
transcription factors and nucleases to their target site in DNA duplex. Despite their 
great potential, TFOs have not been applied in therapy so far. Regarding therapeutic 
use, unmodified TFOs have certain limitations. Some of the limitations are general 
for oligonucleotide therapeutics, such as poor cellular delivery and stability towards 
nucleases, but TFOs have also certain specific challenges: poor triplex stability at 
physiological pH, limited target sequences (polypurine target sequences are usually 
required), and delivery to nucleus. To overcome these limitations, various chemical 
modifications have been developed. 
In recent years, the recognition of double-helical RNA through triplex formation 
has also received increasing interest because of the biological importance of double-
helical RNA structures.14–17 For instance, a large number of noncoding RNAs, RNA 
transcripts that are not transcribed into proteins, are either completely double-helical 
or contain short double-helical regions. MicroRNA (miRNA) precursors are an 
example of such noncoding RNAs. With TFO-based recognition, it would be possible 
to detect these double-helical RNA molecules and interfere with their function. 
However, TFOs usually have higher affinity for DNA duplexes than for RNA 
Introduction 
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duplexes. Recently, the recognition of double-helical RNA by TFPNAs has shown 
promising results.18–31 TFPNAs have been shown to have significantly higher affinity 
for RNA duplexes compared to DNA duplexes.18,20,25 For instance, TFPNAs that bind 
to double-helical regions of messenger RNA have been demonstrated to suppress 
translation in vitro and in cells and to stimulate programmed ribosomal frameshifting 
in vitro.23,28 
1.1 DNA triplexes 
Double-helical DNA is formed by two complementary strands that bind to each other 
through hydrogen bonding between adenine and thymine (A–T) and guanine and 
cytosine (G–C) nucleobases, the Watson–Crick base pairs (Figure 1a). The formation 
of the Watson–Crick base pairs leaves hydrogen bond acceptor and donor groups in 
the major groove of DNA duplex that do not participate in the Watson–Crick 
hydrogen bonding. These acceptor and donor groups may enable the binding of a 
third strand through Hoogsteen or reverse Hoogsteen hydrogen bonding (Figure 
1d).32–35 There are three classes of triple helices that all require an oligopurine-
oligopyrimidine target duplex (TC triplex, GT triplex and GA triplex, Figure 1c).36,37 
In the TC triplex, the third strand is oriented parallel to the polypurine strand of the 
target duplex and forms T*A–T and C+*G–C base triplets through Hoogsteen 
hydrogen bonding. The C+*G–C base triplet requires protonation at the N3 site of 
cytosine (pKa ~ 4.5), and the TC triplex formation is thus limited to acidic conditions. 
In the GT triplex, the third strand can be oriented either parallel or antiparallel to the 
polypurine strand of the target duplex. The parallel triplex is formed through 
Hoogsteen G*G–C and T*A–T triplets and the antiparallel triplex through reverse 
Hoogsteen G*G–C and T*A–T triplets. In the GA triplex, the third strand is 
antiparallel to the polypurine strand of the target duplex and forms reverse Hoogsteen 
G*G–C and A*A–T base triplets. 
Because TFOs bind to DNA duplexes sequence-specifically, they enable targeting 
certain genes by triplex formation. Targeting oligonucleotides to genes is called the 
antigene strategy.1 Compared to the antisense strategy,39,40 which uses antisense 
oligonucleotides that bind to single-stranded messenger RNA (mRNA) by duplex 
formation, one advantage of the antigene strategy is that there are only two copies 
(two alleles) of the target gene in each cell, whereas there may be thousands of copies 
of the corresponding mRNA. Blocking mRNA translation even by sequence-specific 
mRNA cleavage does not prevent the transcription of the corresponding gene, and 
therefore, the mRNAs are resynthesized. The antigene strategy, on the other hand, 
may prevent the mRNA synthesis as long as the antigene oligonucleotide is bound to 
its target gene and not cleaved by nucleases. However, the antigene strategy has 
certain difficulties compared to the antisense strategy, such as delivering the 
therapeutic oligonucleotide to cell nucleus.  One of the main limitations for the use of 
Ville Tähtinen 
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TFOs is the requirement for an oligopurine-oligopyrimidine target duplex. However, 
triple-helix target sequences (TTS) are highly over-represented in the human genome, 
especially at promoter regions.41,42 Orozco et al. suggested that even if TTS are not 
directly targeted by transcription factors, they would act as spacing fragments that 
help the correct positioning of transcription factors. Consequently, TTS would be 
important for gene functionality.  
 
Figure 1.  Schematic presentation of DNA triplexes. a) The structure of DNA and RNA and the 
Watson-Crick base pairs. b) The structure of a parallel TC triplex (PDB 1D 1BWG38). 
c) The three classes of DNA triplexes and the orientation of the triplex-forming strand. 
d) The Hoogsteen and reverse Hoogsteen base triplets. 
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DNA triplexes occur also in nature. H-DNAs are naturally occurring intramolecular 
DNA triplexes that have been suggested to be involved in gene expression 
regulation.12,43–45 For example, an intramolecular triplex in the human c-MYC 
promoter was reported to modulate transcription.46 H-DNAs also induce genome 
instability and they are related to several diseases,12,47,48 such as autosomal dominant 
polycystic kidney disease, lymphomas and Friedreich’s ataxia49. DNA triplexes have 
also been suggested to be present at the catalytic site of DNA polymerases.50 
Recently, MEG3 long noncoding RNA was reported to regulate the TGF-β pathway 
genes through RNA-DNA triplex formation.51 The results suggest that RNA-DNA 
triplex formation may be a general mechanism by which long noncoding RNAs 
recognize their target gene. 
1.1.1 Improving the binding properties and cellular delivery of 
TFOs 
When TFO binds to its target duplex, the resulting triplex is usually 
thermodynamically less stable than the target duplex. In other words, the triplex 
melting temperature is usually lower than that of the duplex (Tm3 < Tm2). One reason 
for the lower thermal stability is the fact there are less hydrogen bonds in the 
Hoogsteen-face than in the Watson–Crick-face (cf. Figure 1d). Additionally, the low 
triplex stability at physiological conditions originates from the charge repulsion 
between the three negatively charged strands. Consequently, the triplex stability can 
be increased with high concentrations of multivalent cations, such as Mg2+,52,53 or 
polyamines.54,55 In the case of purine-rich TFOs, the triplex formation may be 
disturbed by competing structures, such as G-quadruplexes or GA homoduplexes. G-
quadruplexes are stabilized by monovalent cations, such as K+,56 whereas GA 
homoduplexes are stabilized by divalent Mg2+.57 Additionally, under acidic 
conditions, C-rich TFOs can form competing structures that interfere with the triplex 
formation, such as CC+ duplexes and i-motifs.58,59 
The nuclear environment of living cells raises additional challenges for the 
potential in vivo applications of TFOs. The TFO must form a triplex at physiological 
pH and salt concentrations, be nuclease resistant and not be blocked in a stable 
secondary structure. Furthermore, the triplex must be stable enough to have time to 
perform its biological function on the target duplex, for example inhibit transcription 
or target DNA modifying agents. Moreover, the delivery of TFOs to the cell nucleus 
is a challenging task (section 1.1.1.5). To overcome these challenges and to improve 
the binding properties of TFOs, a number of chemical modifications have been 
introduced to TFOs.2 The modifications may be introduced either in the nucleobases 
(section 1.1.1.1), in the phosphodiester backbone (1.1.1.3) or in the sugar moiety 
(1.1.1.2). Moreover, attempting to stabilize triplexes, triplex-binding ligands have 
been studied (1.1.1.4). 
Ville Tähtinen 
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1.1.1.1 Nucleobase modifications 
Aiming to increase the binding affinity of TFOs, various nucleobase modifications 
have been studied (Figure 2). The majority of the modifications have been introduced 
in pyrimidine bases. To improve the stability of TC triplexes at physiological pH, 
cytosine modifications have been developed. 5-methylcytosine (MeC) was shown to 
stabilize triplexes at higher pH already in 1989,60 and more recently, 2-aminopyridine 
derivatives (e.g. MeP) have been used.61–64 Thymidine has also been replaced by 
several modifications, such as 2’-deoxyuridine (dU)65 and 5-(prop-1-ynyl)-2’-
deoxyuridine66. Further triplex stabilization has been obtained by other C-5-(alkyn-1-
yl)-modified TFOs,67–70 such as 5-(1-propargylamino)-2'-deoxyuridine67. The triplex-
stabilizing effect of the C-5-(alkyn-1-yl)-modifications most likely arises principally 
from favorable base stacking interactions. Recently, a thiazole orange intercalator was 
conjugated to the C-5 site of a thymine nucleobase in TFOs to increase the triplex 
stability.71 With three thiazole orange conjugates, the triplex was stabilized by 45 °C 
at pH 7. Moreover, the triplex formation could be detected as an increase in the 
fluorescence signal of thiazole orange.  
Regarding the potential applications of TFOs, the requirement for polypurine-
polypyrimidine target duplexes is one of the limitations. Because the binding of TFOs 
is sequence-specific, any single T-A or C-G base pair interruption reduces strongly 
the triplex stability.72–74 To overcome this sequence limitation, two main approaches 
have been proposed.75 The first approach consists of conjugating intercalators to the 
TFO, aiming to stabilize the triplex containing base pair interruptions in the purine 
strand.76 The drawback of this strategy is the reduced sequence-specificity. The 
second approach is the specific base pair strategy. This strategy consists of 
synthesizing new modified nucleobases capable of forming hydrogen bonds with one 
or both partners of the T-A or C-G base pair inversions.75,77–81 For instance, N4-(2-
guanidoethyl)-5-methylcytosine has been developed to recognize CG inversions and 
N-acetyl-2,7-diamino-1,8-naphtyridine to recognize TA inversions (Figure 2).82 
Consequently, nucleobase-modified TFOs capable of sequence-specific recognition 
of DNA duplexes containing all the four base pairs have been reported.63,82 Section 
1.2.1.1 describes more nucleobase modifications used for the recognition of double-
helical RNA. 
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Figure 2.  Examples of the nucleobase modifications introduced in TFOs. 
1.1.1.2 Sugar modifications 
Several modifications in the sugar moiety of TFOs have also been developed (Figure 
3a). In 1992, Roberts and Crothers reported that RNA third strands form more stable 
triplexes with double-helical DNA compared to DNA third strands.83 This 
observation attracted increasing interest in the development of various ribose 
analogues. 2’-methoxylation (2’-OMe) stabilizes the C3’-endo conformation of the 
ribose sugar (Figure 3b), thus causing less distortion to the target duplex and 
increasing the triplex stability. Furthermore, the 2’-OMe modification prevents 
degradation by RNA nucleases. The 2’-aminoethylribose (2’-AE) modification also 
stabilizes the C3’-endo conformation, and the positive charge of the amino group 
provides additional triplex stabilization.84 
Another successful approach has been to lock the ribose sugar to the C3’-endo 
conformation using locked nucleic acid (LNA) monomers. LNA monomers have an 
O-2’, C-4’-methylene link and they have been shown to increase the binding affinity 
for both single-stranded and double-stranded DNA and RNA.85–88 LNA-modified 
oligonucleotides have also been reported to strand-invade double-stranded DNA 
through Watson–Crick base pairing.87 In addition to the more favorable C3’-endo 
conformation, the reason for the increased binding affinity of LNA may be the 
conformational restriction itself: it is well established that preorganization may reduce 
the entropic penalty of complex formation.89 However, even if LNA monomers 
significantly stabilize triplexes,90,91 fully LNA-substituted TFOs do not form 
triplexes.92 A number of LNA modifications have been developed during the years. 
Ethylene-bridged nucleic acid (ENA) is an LNA homologue that also stabilizes 
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triplexes, although to a smaller extent compared to LNA.93,94 On the other hand, in 
contrast to LNA, fully ENA-substituted TFOs form stable triplexes. Furthermore, the 
stability of LNA-modified TFOs has been increased by introducing other 
modifications within the bridge of the LNA sugar. 2’,4’-BNANC contains a 2’-O, 4’-
C-aminomethylene bridge that allows the substitution of the amino nitrogen.95 
Moreover, a fully 2’,4’-BNANC(NH)-substituted TFO still formed a stable triplex and 
had an improved nuclease resistance. 
 
 
Figure 3.  a) Examples of the sugar modifications introduced in TFOs. b) C3’-endo (N-type, A-
form helices) and C2’-endo (S-type, B-form helices) sugar conformations. 
1.1.1.3 Backbone modifications 
The backbone modifications aim to reduce the electrostatic repulsion upon 
hybridization caused by the negatively charged phosphodiester backbone and to 
improve the nuclease resistance of TFOs. Examples of such backbone modifications 
are phosphorothioates (PS)96, dimethylaminopropyl phosphoramidates 
(PNHDMAPs)97 and peptide nucleic acids (PNAs)98 (Figure 4a). Phosphorothioates, 
in which one of the non-bridging phosphate oxygens is replaced by sulfur, improve 
the nuclease resistance of oligonucleotides. Additionally, phosphorothioates have 
better pharmacokinetic properties than unmodified oligonucleotides.39 This 
improvement results from their enhanced binding to plasma proteins, which prevents 
their rapid excretion in the urine and thus facilitates uptake by tissues. However, if the 
phosphorothioate content in oligonucleotide is high, nonspecific interactions with 
cellular proteins may cause toxic side effects.99 Another drawback of 
phosphorothioates may be their tendency to accumulate in the liver and kidney, 
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although the liver is rich in gene targets for therapeutic oligonucleotides.100,101 
Phosphorothioate modifications are widely used in antisense oligonucleotides.  
PNAs, on the other hand, are synthetic oligonucleotide analogues in which the 
naturally occurring sugar-phosphate backbone is replaced by a peptide backbone 
consisting of N-(2-aminoethyl)glycine units.102 PNAs can hybridize with 
complementary DNA and RNA through Watson–Crick and Hoogsteen base pairing just 
as their natural counterparts, but with higher affinity and sequence-selectivity.103–105 The 
improved affinity results from the neutral peptide backbone that causes no electrostatic 
repulsion upon hybridization, and the relative rigidity of the PNA backbone is 
suggested to be the reason for the improved sequence-selectivity. In addition, PNAs are 
resistant to nucleases and proteases106 and have a low affinity for proteins107. Unlike the 
backbone of nucleic acids, the PNA backbone is non-chiral. Consequently, the binding 
of PNAs to complementary DNA or RNA is not very selective between parallel vs. 
antiparallel strands.  The therapeutic potential of PNAs is limited by their poor cellular 
uptake. Cationic peptides conjugated to PNAs have been shown to enhance the delivery 
of PNAs in cultured cells,27,31,108–112 but entrapment of PNAs within endosomes is 
another challenge yet to overcome (see section 1.1.1.5). 
 
Figure 4.  a) Examples of the backbone modifications introduced in TFOs. b) Schematic 
presentation of the dsDNA–PNA triplexes. 
PNAs were originally designed for recognizing double-helical DNA through triplex 
formation.102 However, it was soon realized that homopyrimidine PNA oligomers 
preferred the triplex invasion binding mode when binding to their oligopurine-
oligopyrimidine target duplex (Figure 4b). In the triplex invasion complex, one PNA 
oligomer binds to the purine strand of the target duplex through Watson–Crick base 
pairing and the other PNA oligomer through Hoogsteen hydrogen bonding. This 
invasion complex is very stable, which has led to the development of bisPNA clamps, 
where two PNA strands, connected by a flexible linker, target the same purine 
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strand.98,113 Interestingly, triplex-forming PNAs (TFPNAs) have significantly higher 
affinity for RNA duplexes compared to DNA duplexes.18,20,25 Therefore, TFPNAs are 
discussed in more detail in section 1.2.1. Although not directly related to Hoogsteen-face 
recognition, an interesting recent approach for recognizing double-helical DNA and 
RNA is using backbone-modified bifacial PNAs.114 These bifacial PNAs are capable of 
invading between the double helix and, owing to modified bifacial nucleobases, capable 
of forming Watson–Crick base pairs with both strands of the target duplex. 
1.1.1.4 Triplex-stabilizing ligands 
Aiming to increase the stability of triplexes, several triplex-stabilizing small 
molecular ligands have been studied.115 The majority of the ligands have been 
heterocycles that intercalate between the triplex bases.116–119 Another approach for 
stabilizing the triplex is using major or minor groove binders. Minor groove binders 
are usually not triplex-specific, and they often even destabilize triplexes because they 
prefer the DNA duplex.120,121 Among the major groove binders, the aminoglycoside 
neomycin has shown the most potential.115,121–129  
Neomycin B (Figure 5a) is one of the aminoglycoside antibiotics discovered to be 
active against tuberculosis in the 1940s.130,131 Neomycin B is very specific for stabilizing 
the DNA triplex without affecting the duplex stability: for example, when 1.67 neomycin 
units/base triplet were added to a poly(dA)•2poly(dT) triplex at pH 6.8, the triplex melting 
temperature Tm3 was increased by 25 °C (from 34 to 59 °C), whereas the duplex melting 
temperature Tm2 was virtually unaffected.122 Additionally, neomycin has been shown to 
improve the cationic lipid-mediated delivery of oligonucleotides in cells.132 The triplex-
stabilizing effect of neomycin originates from its binding to the Watson-Hoogsteen 
groove (Figure 5a). Most aminoglycosides with five or more amino groups are able to 
stabilize DNA triplexes without affecting the duplex stability. However, paramomycin 
stabilized DNA triplex 16 °C less compared to neomycin, although the only difference 
between neomycin and paramomycin is one amino group in ring I replaced by a hydroxyl 
group (cf. structures in Figure 5).121 Ribostamycin, on the other hand, lacking the ring IV 
compared to neomycin, stabilized the triplex only to a small extent. These results indicate 
that the positively charged amino groups in rings I and IV are key factors for the binding 
of neomycin. Neomycin’s affinity for RNA triplex is even higher, but it lacks selectivity 
between RNA triplex and duplex. The binding affinity of neomycin follows the trend: 
DNA duplex < DNA triplex < DNA/RNA hybrids < RNA duplex ~ RNA triplex.115 In a 
recent study conducted in our laboratory, the effect of neomycin site isomers on DNA and 
RNA triplex stability was evaluated.133 Three site isomers, separated by the binding site of 
rings I and II to the ribose sugar, were synthesized (Figure 5c). Interestingly, all the site 
isomers increased the triplex stability almost equally compared to neomycin. 
Consequently, the spatial orientation of the amino groups was favorable for triplex 
binding regardless of the site isomer. 
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Figure 5.  a) The structure of neomycin B with ring numbering and the proposed binding to the 
Watson–Hoogsteen groove of DNA triplex. Reprinted and modified with permission 
from Arya, D. P. Acc. Chem. Res. 2011, 44, 134–146. Copyright (2011) American 
Chemical Society.115 b) The structures of the aminoglycosides paramomycin and 
ribostamycin and the intercalator BQQ. c) The structures of neomycin B site isomers. 
Compared to neomycin, intercalator ligands often show equal or more triplex 
stabilization at low concentrations. At higher concentrations, on the other hand, 
intercalators often tend to stabilize the duplex as well, although more triplex-selective 
intercalators have been developed.116,118,134,135 The most effective triplex-stabilizing 
intercalator to date is benzo[f]quino[3,4-b]quinoxaline (BQQ).136 With 1.5 μmol L–1 
oligonucleotide concentration and 7 equivalents of BQQ relative to the 
oligonucleotide, a TC triplex was stabilized by 51 °C (from 18 to 69 °C) at pH 6.2, 
whereas the duplex was stabilized by 4 °C (from 58 to 62°C). The conjugation of 
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BQQ to neomycin resulted in almost 1000-fold binding constant compared to 
neomycin alone.137 Furthermore, several intercalators and other ligands have been 
covalently conjugated to TFOs to result in remarkable triplex stabilization, for 
example spermine,138 acridine,139 Hoechst 33258,140 cyclopapyrroloindole,141 
benzopyridoindole142 psoralen143 and thiazole orange71 (see section 1.1.1.1). However, 
these ligands have no such selectivity for triplex vs. duplex stabilization as compared 
to neomycin. Surprisingly, covalent conjugation of neomycin to TFOs and its effect 
on the triplex stability was not reported before our studies described in section 3.1. 
Several studies describe the conjugation of oligonucleotides and PNAs with 
neomycin. The neomycin–oligonucleotide conjugates have been reported to stabilize 
DNA and RNA duplexes to some extent. For example, neomycin, covalently attached 
to the C-5 position of a 2’-deoxyuridine residue in  DNA-oligonucleotide, enhanced 
duplex formation with an α-sarcin loop RNA target.144 Additionally, neomycin 
conjugated to 2’-OMe oligoribonucleotides enhanced invasion to a HIV-TAR RNA 
model.145 
1.1.1.5 Improving the cellular delivery of TFOs 
As with all therapeutic oligonucleotides, the delivery of TFOs to their intracellular 
target is a challenging task. The cellular uptake of unmodified oligonucleotides is 
inefficient.146 The large size, hydrophilicity and the anionic backbone of 
oligonucleotides prevent their direct permeation through the cell membrane surface. 
Oligonucleotides enter the cells via either adsorptive or receptor-mediated 
endocytosis, thus resulting in vesicular uptake.146–149 The ionic repulsion between the 
negatively charged oligonucleotide and cell membrane disturbs the adsorption to the 
cell surface. However, the cellular uptake cannot be improved by eliminating the 
negative charge alone, as demonstrated by the poor cellular uptake of neutral 
oligonucleotide analogs, such as PNA.147 After entering the cytoplasm, the 
oligonucleotide vesicles are delivered to the endosome-lysosome compartment. 
Endosomes are membranous organelles that act as sorting compartments in cells. The 
oligonucleotide must be able to escape the endosome to reach its site of action in the 
cytoplasm or nucleus. If the oligonucleotide gets trapped in the endosome, as it often 
does, it is likely to be degraded by lysosomes.  
To facilitate the cellular uptake of oligonucleotides, three main strategies have 
been developed.150 One strategy is to use chemically modified oligonucleotides, such 
as phosphorothioates39. Unlike unmodified oligonucleotides, phosphorothioate 
oligonucleotides can slowly cross the endosomal lipid bilayer to escape endosomes 
into the cytoplasm or nucleus by an unknown mechanism called gymnosis.151–155 The 
second strategy relies on molecular, macromolecular or supramolecular carriers that 
form non-covalent complexes with oligonucleotides. These carriers include cationic 
lipids, dendrimers, polymers, cyclodextrins and carbon nanotubes. For instance, 
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dendrimers, highly branched 3D molecules, were demonstrated to enhance the 
cellular uptake of TFOs by forming TFO–dendrimer nanoparticles.156  
The third strategy for improving the cellular delivery of oligonucleotides is using 
covalently bound oligonucleotide conjugates, for instance cell-penetrating peptides, 
ligands for cell surface receptors and lipophilic substituents, such as cholesterol 
(Figure 6). Cholesterol conjugation to TFOs has been shown to enhance the cellular 
uptake by liver cells.157 Furthermore, the cholesterol–TFO conjugate inhibited 
transcription in vitro.157 Cationic groups have also been conjugated to TFOs, aiming 
to reduce the ionic repulsion upon hybridization and enhance cellular permeation. 
One potential cationic conjugate is the guanidinium group, the functional group of 
arginine. The guanidinium group is highly basic (pKa = 12.5) and thus, it remains 
protonated under a wide pH range. Guanidinium modifications have been shown to 
improve the cellular uptake when introduced either in the nucleobase158 or in the 
backbone159 of oligonucleotides. Guanidinium modifications also improve the cellular 
uptake of PNA.160,161 As discussed previously, the cellular uptake of PNAs can also be 
improved by conjugation with cationic peptides.27,31,108–112 Conjugation of TFOs with 
ligands that bind to cell surface receptors, on the other hand, could allow cell-specific 
targeting.162 Carbohydrates, in particular N-acetylcalactosamines (GalNAc),163,164 are 
a widely studied example of such ligands. 
 
Figure 6.  Examples of the conjugate groups reported to improve the cellular uptake of TFOs 
and other oligonucleotides. 
Compared to antisense approaches for single-stranded RNA, targeting dsDNA in the 
cell nucleus raises an additional challenge. DNA is typically bound to histones and 
tightly packed into chromatin, which may prevent TFO from accessing its target 
sequence. However, various demonstrations of triplex formation in chromosomal 
environment have been reported.165 In general, the nuclear entry itself may not be the 
rate-limiting step for therapeutic oligonucleotides, as phosphorothioate 
oligonucleotides are demonstrated to continuously shuttle between the nucleus and 
cytoplasm.166 
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1.1.2 Potential applications of TFOs 
 
Figure 7.  Examples of the potential applications of TFOs. a) Blockage of transcription or 
replication elongation. b) Blockage of transcription or elongation initiation complex. c) 
Site-specific cleavage of the target duplex. d) Site-specific targeting of drugs, 
enzymatic effectors (transcription factors, restriction enzymes), cross-linking agents, 
fluorophores etc. 
1.1.2.1 Modulating transcription and replication via triplex formation 
By binding to the major groove, TFOs can prevent specific proteins from recognizing 
the DNA duplex.1,167–169 Various in vitro studies have shown that TFOs can modulate 
gene expression by inhibiting the transcription, by interrupting either the binding of 
transcription factors170,171 or the formation of the initiation complex172 (Figure 7b). 
TFOs can also stop transcription elongation, either alone or conjugated to psoralen or 
other DNA damaging agents (Figure 7 a & d).173–175 
On the other hand, TFOs can be used to increase gene expression. Human β-
globin disorders, such as sickle cell anemia and β-thalassemia, can be treated by 
increasing the transcription levels of certain genes. For example, TFO-psoralen 
conjugate was used to direct psoralen-induced mutation site-specifically to the γ-
globin gene transcription factor binding site.176 This mutation resulted in 4-fold 
activation of gene expression. Additionally, a TFO conjugated to transcriptional 
activation domains derived from Herpes simplex virus protein 16 (VP16) was 
demonstrated to activate the expression of the target gene.177 The activation of 
transcription has also been demonstrated in vivo in Saccharomyces cerevisiae cells.177 
The authors used a TFO with a hairpin residue that has a binding site for GAL4 
protein, a transcription activator. Furthermore, transcription can be activated by 
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targeting TFO to the gene repressor region, thus stimulating the expression of the 
gene in interest.178,179 TFOs have also been reported to inhibit replication.50,180 In vitro 
studies show that DNA polymerase elongation can be inhibited by targeting TFOs 
upstream181 or downstream182,183 the initiation site.  
1.1.2.2 Introducing or correcting mutations site-specifically 
TFOs have been used to induce DNA damage site-specifically to their target duplex, 
thus causing mutation and recombination to the target site both in vitro and in vivo 
(Figure 7 c & d).184,185 UV light, alkylating agents and photoreactive molecules such 
as psoralen have been shown to cause recombination, but not site-specifically. 
However, conjugating DNA damaging agents to TFOs enables site-specific targeting. 
Various damaging agents have been conjugated to TFOs, such as photoactivable 
agents,186 metal complexes,187 orthophenantroline,188 nucleases189 and restriction 
enzymes. For instance, the restriction enzyme PvuII was used to cleave DNA site-
specifically.190 Psoralen–TFO conjugates, on the other hand, have been employed in 
targeting site-specific mutations through the formation of base pair -specific psoralen 
adducts.191 Psoralen–TFO conjugates were also demonstrated to form cross-links in 
the target DNA in cultured cells.192 TFOs itself, without conjugation, have also been 
reported to induce recombination through a nucleotide excision repair (NER) -
dependent pathway.193 Recently, TFPNAs have been demonstrated to stimulate the 
correction of gene mutations: TFPNAs stimulated the correction of a splice-site 
mutation in the β-globin gene,194 and γ-modified TFPNAs induced the correction of 
anaemia in β-thalassemic mice in vivo.195 
1.1.2.3 Tools for biotechnology and nanotechnology 
In addition to being used in the modulation of gene expression, TFOs can also be 
employed as biotechnological tools.2 TFOs can be employed in targeting drugs to 
specific sites of DNA, site-specific DNA labeling and in the recognition and 
purification of DNA. For instance, a TFO conjugated with camptothecin, a 
topoisomerase I inhibiting drug, stimulated cleavage at the DNA target site.196 TFOs 
bearing a fluorescence probe, on the other hand, were used to label chromosomes in 
cell nucleus.197 TFOs have also been used to purify their target duplex from a 
bacterial lysate by immobilizing the TFOs on an affinity chromatography support.198 
At low pH, the TFO bound its target duplex from the lysate, and the target duplex 
could eventually be released from the support by eluting with alkaline buffer. 
Additionally, TFOs can be applied for the recognition of protein binding sites on 
DNA, since the third strand can act as a competitor for the DNA-binding protein.199 
Furthermore, DNA triplexes have great potential in DNA nanotechnology, a rapidly 
developing research area.200,201 
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1.1.2.4 Recognition of the nucleobase content in the target DNA duplex by 
TFO probes 
One potential application for TFOs is using them as sensors for recognizing 
nucleobase content in the target duplex. In cytogenetic research and clinical 
diagnosis, there is a strong need for the sequence-selective detection of nucleic acid 
sequences. For instance, single-nucleotide polymorphisms (SNPs) and other irregular 
DNA structures are considered to play a major role in the production of nonfunctional 
proteins.202 Therefore, detecting SNPs would be important for monitoring various 
biological processes and identifying genetic mutations of inherited diseases. For 
clinical diagnosis, labeled TFOs could provide a convenient method to detect nucleic 
acid sequences directly from cell, with no need for amplification steps such as PCR 
(polymerase chain reaction). Several methods for detecting SNPs have been 
developed,203–211 many of which rely on changes in hybridization energies. However, 
the differences in the hybridization energies tend to be small between complementary 
oligonucleotide strands and oligonucleotides containing a single nucleotide mismatch.  
Fluorescence-labeled oligonucleotide probes have the potential to increase the 
sensitivity of the recognition, if the fluorescence label shows marked change in the 
fluorescence intensity between the hybridized and non-hybridized probe. Fluorescent-
labeled oligonucleotide probes have been developed for recognizing SNPs in single-
stranded DNA.212,213 The recognition was based on either duplex formation212 or 
triplex formation with a clamp-type TFO.213 Additionally, fluorescent-labeled TFOs 
have been used for specific labeling of genomic DNA duplexes.197 A fluorescent-
labeled TFO probe that recognizes Watson–Crick base pair inversions in double-
stranded DNA was demonstrated by Pedersen et al. (Figure 8).214 A pyrene moiety at 
the 3’-position of a uridine residue was used as the fluorescent label. The TFO probe 
showed a drastic increase in fluorescence upon binding to complementary dsDNA, 
but only marginal change in the fluorescence was observed upon binding to dsDNAs 
with single base pair inversions. The single base pair inversions resulted in a 
Hoogsteen mismatch between the TFO and the dsDNA. Because all three Hoogsteen 
mismatches resulted in a very weak fluorescence signal, the TFO probe was unable to 
discriminate the Hoogsteen mismatches from each other. 
Recently, 19F NMR based sensors, because of their sensitivity to local 
environments, have also been developed for the recognition of SNPs and other 
irregular DNA structures. Tanabe et al. introduced a 19F-labeled nucleobase 
modification into oligonucleotides and were able to detect mismatched and bulged 
structures in ssDNA.215 Hocek et al. used biaryl-substituted nucleobases as dual 
fluorescent and 19F NMR probes capable of detecting mismatches, deletions and 
hairpins in ssDNA.216 These examples both required duplex formation between the 
target ssDNA and the labeled oligonucleotide strand. Sakamoto et al. developed an 
external 19F NMR probe capable of detecting nucleobase content in dsDNA.217 This 
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3,5-bis(trifluoromethyl)-phenyl-modified bisbenzimide H33258 probe binds to the 
minor groove of an AATT sequence of dsDNA. The 19F NMR shift of the probe was 
sensitive to the base pairs adjacent to the AATT binding site, and the probe was able 
to recognize bulge structures and all the four different base pairs neighboring the 
binding site.218 Section 3.2 describes 19F-labeled TFO probes capable of 
discriminating variable nucleobases in the pyrimidine strand of dsDNA. 
 
Figure 8.  The principle of the pyrene-labeled fluorescent TFO probe for the recognition of 
Watson–Crick base pair inversions in dsDNA.214 
1.2 RNA triplexes 
Compared to DNA triplexes, RNA triplexes have received relatively little attention. 
However, the biological importance of RNA triple helices has started to reveal in 
recent years.45,219–222 Naturally occurring RNA triplexes are ubiquitous and important 
for folding RNAs into complex tertiary structures that are crucial for their biological 
functions. Some examples of biologically important RNAs with triple-helical regions 
include long noncoding RNAs (lncRNAs),223–226 telomerase RNAs,227–232 metabolite-
sensing riboswitches,233–241 ribosomal RNAs,242–244 mRNA pseudoknots that induce –
1 ribosomal frameshifting,245–250 group I introns251–253 and group II introns254. 
Moreover, the molecular recognition of double-helical RNA through triplex 
formation has attracted increasing interest in recent years because of the central role 
of noncoding RNAs in cellular processes and gene expression.14–17 A large number of 
noncoding RNAs, RNA transcripts that are not transcribed into proteins, are either 
completely double-stranded or contain short double-helical regions. For instance, 
microRNA (miRNA) precursors adopt a double-stranded form. Since the involvement 
of miRNAs in cancer development was demonstrated in 2002,255 miRNAs have been 
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the mostly studied noncoding RNAs. Therefore, the TFO-based recognition of 
double-helical RNA is an appealing research field.  
The TFOs that target double-helical RNA are usually pyrimidine strands that bind 
to the major groove of oligopurine-oligopyrimidine target duplex in parallel 
orientation (parallel pyrimidine motif RNA triplex, cf. TC triplex in Figure 1c).222 The 
TFOs bind to the target duplex through Hoogsteen hydrogen bonding to form 
(T/U)*A–U and C+*G–C base triplets. Also other types of major groove RNA 
triplexes may form.256 One of the major limitations in targeting RNA duplexes by 
TFOs is that TFOs usually have higher affinity for DNA duplexes than for RNA 
duplexes. Because RNA duplex adopts an A-form helical structure, the major groove 
is relatively deep and narrow compared to B-form DNA duplex. For example DNA 
and 2’-OMe-RNA based TFOs only bind to DNA but not to RNA duplexes.83,88,257–260 
DNA as the third strand probably cannot find optimal geometry for binding to A-form 
RNA duplex, and the 2’-OMe may cause steric hindrance with the RNA duplex. In 
addition to Hoogsteen hydrogen bonding, naturally occurring RNA triplex is also 
stabilized by backbone–backbone hydrogen bonding between the 2’-OH from the 
third strand and a non-bridging phosphate oxygen from the purine strand of the target 
duplex. The additional 2’-OH–phosphate hydrogen bond is missing with DNA or 2’-
OMe-RNA as the third strand. It is worth noting that 2’-OMe modification enhances 
the binding of TFOs to DNA duplexes, probably due to the geometrical compatibility 
with the major groove of DNA duplex. LNA modifications, on the other hand, have 
been shown to stabilize TFO/(RNA)2 triplexes as well as TFO/(DNA)2 triplexes.88,261 
This stabilization is probably caused by the TFO backbone preorganization and steric 
compatibility, despite the lack of the 2’-OH–phosphate hydrogen bond. 
1.2.1 Recognition of double-helical RNA by triplex-forming 
peptide nucleic acids (TFPNAs) 
One promising approach for the recognition of double-stranded RNA is using triplex-
forming peptide nucleic acids (TFPNAs) instead of TFOs.18–31,262,263 As described in 
section 1.1.1.3, PNAs were originally designed for the recognition of double-helical 
DNA. However, TFPNAs have been shown to have significantly higher affinity for 
RNA duplexes compared to DNA duplexes.18,20,25 The reason for this difference in 
binding affinity is not yet completely understood and requires X-ray crystallography 
and NMR studies, but the neutral and flexible PNA backbone probably provides 
favorable geometry and backbone-backbone interactions to the deep and narrow 
major groove of RNA duplex.222 A recent NMR study suggests that hydrogen bonding 
between N-H of TFPNA backbone and non-bridging phosphate oxygen of RNA may 
be behind the higher affinity of TFPNAs for RNA.264 Aiming to improve the binding 
properties of TFPNAs, various modifications have been introduced either in the 
nucleobases or in the backbone of TFPNAs. 
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1.2.1.1 Nucleobase modifications 
The standard major-groove U*A–U base triplet is very common in natural RNAs. In 
TFPNAs, the uracil residue is often replaced by thymine for the recognition of A–U 
base pairs to form T*A–U triplets. As discussed previously, the C+*G–C triplet 
requires low, non-physiological pH to fully protonate C (pKa ~ 4.5). To overcome this 
pH dependence, a number of modified nucleobases have been developed for the 
recognition of G–C base pairs (Figure 9). The pseudoisocytosine modification (J, a 
neutral analogue of protonated cytosine, Figure 9) significantly alleviates the pH 
dependency of PNA/(DNA)2113,265 and PNA/(RNA)220,25 triplex formation. The 
binding affinity for RNA duplexes has been further increased by a 2-aminopyridine 
nucleobase modification (M, pKa ~ 6.7, Figure 9) that forms M+*G–C triplets.25 M-
modified PNAs form stable and sequence-selective triplexes at physiological 
conditions, and they have been reported to be highly selective for double-stranded 
RNA over DNA.25 The positive charge of M is probably a key factor in the increased 
binding affinity. Additionally, M has been shown to enhance the cellular uptake of 
PNAs.31 L, a thiolated derivative of the J, has also been reported to enhance the 
recognition of G–C base pairs at physiological conditions compared to J.20 
Importantly, the L-modified PNA bound selectively to double-stranded RNA, 
showing relatively weak binding to double-stranded DNA, single-stranded DNA and 
single-stranded RNA. 
The binding of a pyrimidine strand through triplex formation requires a 
polypurine strand in the target RNA duplex. However, in naturally occurring RNA 
duplexes, the purine strand is often interrupted by inverted Watson–Crick U-A and C-
G base pairs. For example in microRNAs and other noncoding RNAs, it is common 
to find eight or more consecutive purine bases interrupted by a couple of pyrimidines. 
For the recognition of these pyrimidine inversions, several modified nucleobases have 
been developed (Figure 9). For the recognition of the C-G inversion, PNAs modified 
with 5-methylisocytosine (iC)19, 2-pyrimidinone (P)266,267, Pex24 and Q262 have been 
reported. The iC modification slightly increases the affinity for the target RNA 
duplex, but the base-selectivity is low.19 The P modification shows relatively good 
base-selectivity, but the binding affinity is low.24 The binding affinity can be 
improved using the Pex modification with an additional linker between the PNA 
backbone and P nucleobase.24 The Pex modification has modest base-selectivity at pH 
5.5, but interestingly, the base-selectivity improves significantly at pH 6.25. The best 
C-G inversion recognition has been reported with the guanidine-modified Q.262 Q 
shows high binding affinity, base-selectivity and selective binding to dsRNA over 
ssRNA. Furthermore, the incorporation of multiple Q residues to PNAs improves the 
cellular uptake. For the recognition of the U-A inversion, on the other hand, the 3-
oxo-2,3-dihydropyridazine nucleobase (E) has shown promising results.24 In the 
future, extended nucleobases, capable of recognizing both nucleobases of the base 
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pair, may be a feasible option for the recognition of pyrimidine inversions (cf. Q). 
Furthermore, as discussed previously, the RNA triplex stability can be increased with 
small molecular ligands, such as neomycin.115 
 
Figure 9.  Modified PNA nucleobases developed for the recognition of G-C base pairs and 
pyrimidine inversions in double-stranded RNA. 
1.2.1.2 PNA backbone modifications 
The binding affinity of TFPNAs for dsRNA can also be improved by conjugating 
cationic peptides, such as lysine and arginine, to the backbone of TFPNAs.27 
Moreover, the cationic peptides maintained the sequence-selectivity of the TFPNAs 
and improved their cellular uptake. Another approach for enhancing the binding 
affinity and selectivity of PNAs is modifying their backbone with chiral units. The 
chiral units may provide suitable preorganization that improves binding to DNA and 
RNA targets. The binding of chiral PNAs to single-stranded RNAs has been 
thoroughly studied.268–273 For example, α-guanidine modified PNA (α-GPNA, Figure 
10a), where D-arginine was incorporated to every other position of the backbone 
instead of glycine, sustained strong and sequence-selective binding to complementary 
single-stranded RNA.270 Furthermore, antisense PNAs bearing chiral arginine units at 
the α and γ positions have been shown to inhibit miR-210 activity in cells.271 In 
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addition to beneficial preorganization, the guanidinium groups improved the cellular 
uptake of PNA and increased water solubility.160,161 However, before our studies 
described in section 3.3, the ability of chiral TFPNAs to recognize RNA duplexes was 
demonstrated in only one report by Rozners et al.26 In this report, the binding of 
triplex-forming α-GPNAs to double-helical RNA hairpins was studied. According to 
isothermal titration calorimetry (ITC), the α-GPNAs had reduced affinity and 
sequence-selectivity for the RNA hairpins. The data also suggested that α-GPNA 
preferred a 2:1 (PNA)2/RNA triplex invasion complex instead of stoichiometric 
PNA/RNA triple helix (cf. Figure 10b). 
 
Figure 10. a) The recognition of a double-helical RNA hairpin by α-GPNAs (Rozners et al.)26 and 
the potential sites for chiral substituents in the PNA backbone (α–γ). b) Examples of 
the potential binding modes of PNAs to RNA hairpins. 
1.2.2 Potential applications 
A large number of biologically important noncoding RNAs are either completely 
double-helical or contain short double-helical regions. Accordingly, TFO-based RNA 
recognition has various potential RNA targets and applications.222 For instance, 
miRNAs are involved in many gene regulation processes associated with diseases 
such as cancer.16,255 Cellular miRNAs are maturated from double-helical hairpin 
 
Ville Tähtinen 
 32 
precursors (pre-miRNAs) that are transported from the nucleus to the cytoplasm and 
eventually cleaved by the RNase enzyme Dicer into double-stranded miRNAs. 
MiRNA activity can be inhibited by antisense oligonucleotides, referred to as anti-
miRs. However, the antisense-based recognition of dsRNA requires a strand invasion, 
where the antisense oligonucleotide must be able to replace one strand in dsRNA. The 
TFO-based recognition, on the other hand, does not disrupt the secondary structure of 
the target RNA, which presumably fastens the binding. In 2012, Zengeya et al. 
developed a nucleobase-modified TFPNA that binds to a pre-miRNA-215 hairpin 
model with high affinity at physiological conditions (see PNA4 and ORN2 in Figure 
23).25  
 
Figure 11.  –1 programmed ribosomal frameshifting stimulation by TFPNAs. Reprinted with 
permission from Puah, R. Y.; Jia, H.; Maraswami, M.; Kaixin Toh, D.-F.; Ero, R.; 
Yang, L.; Patil, K. M.; Lerk Ong, A. A.; Krishna, M. S.; Sun, R.; Tong, C.; Huang, M.; 
Chen, X.; Loh, T. P.; Gao, Y.-G.; Liu, D. X.; Chen, G. Biochemistry 2018, 57, 149–
159. Copyright (2018) American Chemical Society.23  
To date, nucleobase-modified TFPNAs that bind to hairpin structures in mRNA have 
been demonstrated to suppress translation in vitro and in cells and to stimulate –1 
programmed ribosomal frameshifting in vitro (Figure 11).23,28 Many viruses and 
bacteria utilize –1 programmed ribosomal frameshifting (–1 PRF) to increase the 
information content in their genomes.274 –1 PRF can be activated by several 
stimulatory elements such as a heptameric slippery sequence (X XXY YYZ) and an 
mRNA secondary structure (hairpin or pseudoknot) that is positioned 2–8 nucleotides 
downstream from the slippery site. For example, HIV-1 mutants with enhanced −1 
PRF efficiencies are significantly less infectious.275 Consequently, TFPNAs that 
stabilize –1 PRF stimulating RNA structures are potential antiviral agents. Recently, a 
nucleobase-modified TFPNA was also demonstrated to inhibit influenza viral 
replication by targeting a double-stranded region in viral RNA.276 In addition, 
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TFPNAs may find applications in inhibiting the binding of proteins to dsRNA and in 
recognizing certain RNA duplexes.222 
1.3 Methods for investigating triplexes 
1.3.1 Conventional methods 
Several methods have been used for studying triplexes, for example ultraviolet 
(UV),277,278 circular dichroism (CD)279,280 and nuclear magnetic resonance 
(NMR)34,38,281 spectroscopy, fluorescence-based techniques,282,283 gel 
electrophoresis35,284 and isothermal titration calorimetry (ITC)285,286. Among these 
methods, the UV thermal denaturation study is probably the most used experiment. 
With the thermal denaturation study, the stability of the nucleic acid secondary 
structures, such as triplex or duplex, can be determined. The conformational changes 
of nucleic acids upon heating often result in changes in their UV absorbance. In most 
cases, the thermal denaturation experiment can be performed by recording the 
absorbance at 260 nm as a function of temperature. For example, duplex and triplex 
denaturation lead to an increase in the absorbance (hyperchromism) at this 
wavelength. To be able to determine duplex and triplex melting temperatures by UV 
spectroscopy, the difference between the duplex and triplex melting temperatures 
must be large enough. The denaturation of cytosine-containing triplexes can be 
detected more specifically by using 295 nm as the detection wavelength.277 At 295 
nm, the denaturation can be observed as a decrease in the absorbance 
(hypochromism), caused by the partial deprotonation of the cytosine nucleobases in 
the triplex-forming strand upon unfolding. CD spectroscopy can also be used to 
monitor triplex denaturation, even if triplexes do not have a characteristic CD 
spectrum like A-form helices, for instance.280 1H NMR, on the other hand, allows the 
detection of Hoogsteen hydrogen bonding.281 
1.3.2 19F NMR spectroscopy 
19F NMR spectroscopy has been shown to be a valuable tool for investigating 
biological events and biomolecules, including nucleic acids.287  The 19F nucleus has 
several favorable properties for NMR spectroscopy.288–290 It has a spin of ½, 100% 
natural abundance and a high gyromagnetic ratio. 19F has a high sensitivity, 83% of 
that of 1H, and much higher compared to 13C, 15N and 31P (approximately by a factor 
of 27, 250 and 8, respectively). Importantly, the chemical shift of 19F is very sensitive 
to changes in the local environment of the nucleus, and the chemical shift range is 
wide, over 400 ppm for organofluorine compounds. Additionally, because of the 
absence of fluorine in nucleic acids and biological systems, there are no interfering 
background signals. 1H NMR studies on large nucleic acid molecules are often 
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disturbed by the abundance of protons that need to be assigned and the severely 
overlapping signals within a narrow chemical shift range. The strength of 19F NMR 
spectroscopy arises from the relatively simple one-dimensional (1D) spectra that can 
provide insight into complex nucleic acid structures. The drawback of 19F NMR is 
that a fluorine probe or label has to be incorporated into the nucleic acids (or nucleic 
acid binding ligands) under study.291 To make sure that the labeling causes no 
significant changes in the native properties of the nucleic acids, the influence of the 
fluorine modification should be thoroughly evaluated. Compared to 
spectrophotometric methods (UV, CD and fluorescence), NMR spectroscopy is 
relatively insensitive. However, 19F NMR spectroscopy has been demonstrated to 
provide more detailed information on coexisting structures and local environments 
and local denaturation of nucleic acids.287,288,290,291 19F NMR is often used in 
combination with other methods rather than being used as a competitive alternative 
for other techniques. 
19F NMR has been used to study nucleic acid structures such as aptamers,292–294 
viral regulatory hairpins,295–300 riboswitches,301–304 ribozymes,305–307 DNA 
adducts308,309 and G-quadruplexes310–314. Both DNA315,316 and RNA317 triplexes have 
also been studied by 19F NMR. The monitoring of triplex formation by 19F NMR was 
reported for the first time by Tanabe et al.315 The authors introduced a 2’-deoxy-5-
fluorouridine label into a TFO and monitored the binding of the TFO to its target 
duplex (Figure 12a). The TFO was a C-rich pyrimidine oligonucleotide, and thus 
required slightly acidic conditions for the triplex formation (pH 5.5). The TFO alone 
gave multiple signals at 25 °C, indicating the formation of unspecific secondary 
structures that are often formed by C-rich nucleic acids under acidic conditions.58,59 
This suggestion was confirmed by the fact that at neutral pH or at elevated 
temperature, only one 19F resonance signal was observed. Triplex formation with the 
target duplex resulted in a marked change in the chemical shift of the 19F resonance 
signal, albeit the signal was relatively broad. Additionally, our group developed a 
sensitive 4’-C-[(4-CF3-1H-1,2,3-triazol-1-yl)methyl]thymidine sensor that allowed 
convenient monitoring of DNA single strand–duplex–triplex conversions by 19F NMR 
(Figure 12b).316 Furthermore, for the detection of RNA secondary structures, 
including triplexes, a 2’-O-[(4-CF3-triazol-1-yl)methyl]uridine sensor was 
developed.317 The sensors were incorporated into oligonucleotides as 
phosphoramidites and they caused only marginal effects on the stability of DNA and 
RNA models. 
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Figure 12.  Triplex formation monitored by 19F NMR spectroscopy using a) 2’-deoxy-5-
fluorouridine sensor315 or b) 4’-C-[(4-CF3-1H-1,2,3-triazol-1-yl)methyl]thymidine 
sensor316. a) Spectra reprinted and modified from Tanabe, K.; Sugiura, M.; Nishimoto, 
S. I. Bioorganic Med. Chem. 2010, 18, 6690–6694, Copyright (2010), with permission 
from Elsevier.315 b) Spectra reprinted and modified with permission from Granqvist, L.; 
Virta, P. J. Org. Chem. 2014, 79, 3529–3536. Copyright (2014) American Chemical 
Society.316 
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2 Aims of the Thesis 
Triplex-forming oligonucleotides (TFOs) have received considerable interest because 
of their potential as therapeutic agents that sequence-selectively recognize double-
helical DNA and RNA. The recognition of double-helical DNA is the basis of the 
antigene therapy, the aim of which is to control the function of a certain gene by 
triplex formation. In recent years, the recognition of double-helical RNA has become 
highly attractive because of the central role of noncoding RNAs in gene expression. A 
large number of noncoding RNAs are either completely double-stranded or contain 
short double-stranded regions. For instance, microRNA (miRNA) precursors adopt a 
double-helical form. The first aim of this thesis was to develop modified TFOs and 
triplex-forming peptide nucleic acids (TFPNAs) that have high affinity for DNA and 
RNA duplexes especially under physiological conditions. To increase the binding 
affinity for DNA duplexes, neomycin was conjugated to various positions of triplex-
forming DNA oligonucleotides. To increase the binding affinity for RNA duplexes, 
chiral γ-(R)-hydroxymethyl and γ-(S)-guanidinylmethyl backbone modifications were 
introduced to TFPNAs.  
The second aim of this thesis was to provide further information on the competing 
mechanisms by which TFPNAs bind to double-helical miRNA. These binding 
mechanisms include 1:1 PNA/RNA triplex and 2:1 (PNA)2/RNA triplex invasion 
complex. This information was obtained especially by using 19F-labeled miRNA 
targets and 19F NMR spectroscopy, which is a simple option to discriminate different 
ways of binding.  For the potential therapeutic use of TFPNAs in the future, it is 
crucial to discriminate the different binding modes and to ensure the selectivity of the 
binding. Furthermore, the objective of the chiral backbone modifications was to 
provide suitable preorganization for 1:1 PNA/RNA triplex formation, in addition to 
increasing the binding affinity. Moreover, the chiral modifications would have the 
potential to increase the cellular uptake of PNAs. The third aim of this thesis was to 
develop 19F-labeled TFOs that are able to recognize variable nucleobase content in the 
pyrimidine strand of double-helical DNA. These 19F-labeled TFOs may find 
applications in studies that aim to simultaneously detect changes of local 
environments in structurally resembling double-helical regions e. g. upon binding of 
nucleobase-specific ligands. 
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The aims of the thesis may be summarized as follows: 
i. To develop modified TFOs (I; section 3.1) and TFPNAs (II and IV; section 
3.3) that have high affinity for DNA and RNA duplexes especially under 
physiological conditions. 
ii. To provide detailed information on the competing mechanisms by which 
TFPNAs bind to double-helical miRNA and to improve the selectivity for 
stoichiometric PNA/RNA triplex formation by chiral modifications (II and IV; 
section 3.3). 
iii. To develop 19F-labelled TFOs that are able to recognize nucleobase content in 
the pyrimidine strand of double-helical DNA (III; section 3.2). 
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3 Results and Discussion 
3.1 DNA triplex stabilization by neomycin-
conjugated TFOs 
 
Figure 13.  The DNA target duplexes and the neomycin-conjugated TFOs (ODN2–ODN7 and 
ODN9) studied herein. 
In the first section of this thesis, neomycin units were conjugated to variable sites 
of TFOs and their effect on DNA triplex stability was studied (ODN2–7 and 
ODN9, Figure 13). The neomycin units were conjugated either to the C-5 site 
(ODN2), C-2’ site (ODN3) or C-4’ site (ODN4) of a thymidine residue, and the 
conjugation site within the TFO sequence was also varied (ODN2 vs. ODN5 and 
ODN6). For the synthesis of the conjugates, three different alkyne-modified 
phosphoramidite building blocks (1–3, Figure 14) were synthesized and 
incorporated into the TFOs by automated DNA synthesis. An azide-derived 
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neomycin (4) was then coupled to the terminal alkynes on solid support using the 
“click” chemistry conditions (1,3-dipolar Huisgen cycloaddition). Finally, the 
neomycin-conjugated TFOs were released from the solid support and deprotected 
using concentrated aqueous ammonia. The influence of the neomycin units on the 
triplex stability was evaluated at slightly acidic conditions (pH 5.5 and 6.0) by 
comparing the triplex melting temperatures (Tm3) obtained from the UV thermal 
melting profiles at 260 and 295 nm. Additionally, more detailed information on the 
triplex/duplex/single strand conversion was provided by 19F NMR spectroscopic 
analysis using 19F-labeled target duplexes (19F-duplex 1–3, Figure 13). 
3.1.1 Synthesis of C-5, C-2’ and C-4’-neomycin-conjugated 
TFOs 
3.1.1.1 Building blocks 1–4 
 
Figure 14.  Alkyne-modified phosphoramidite building blocks 1–3 and azide-derived neomycin 
4 used for the synthesis of neomycin-conjugated TFOs. 
For the synthesis of the neomycin-conjugated TFOs, three nonstandard 
phosphoramidite building blocks (1–3) and an azide-derived neomycin (4) were 
synthesized (Figure 14). The synthesis of compounds 1 and 2 is described in 
Scheme 1. For the synthesis of compound 1, commercially available 3’,5’-O-
(1,1,3,3-tetraisopropyl-1,3-disiloxanediyl)uridine (5) was first converted into acetal 
6 via SN1 type alkylation with methyl[(pent-4-yn-1-yloxy)methyl]sulfide. The 
disiloxanediyl protection of compound 6 was then removed with 
tetrabutylammonium fluoride and the exposed 5’-OH group was protected with a 
4,4’-dimethoxytrityl group to yield compound 7. Finally, phosphitylation of the 3’-
OH group gave compound 1 in 56% overall yield. For the synthesis of compound 
2, 5’-(4’4’-dimethoxytrityl)-4’-C-azidomethylthymidine (8) was first synthesized 
from thymidine in 49% yield following a protocol previously developed in our 
laboratory.318 Compound 8 was then converted into compound 9 via Cu(I)-
catalyzed 1,3-dipolar cycloaddition with dipropargyl ether. Finally, phosphitylation 
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of the 3’-OH group gave compound 2 in 35% overall yield (calculated from 
thymidine). In compound 2, the triazolyl-bridge that links the alkynyl moiety to the 
C-4’ of thymidine was introduced mainly for synthetic reasons. Previously, our 
group used a C-4’-alkynylaminomethyl thymidine derivative for the synthesis of 
neomycin-conjugated oligonucleotides, but the synthesis of this derivative was 
relatively complex.319 Correspondingly, a C-4’-alkynyloxymethyl thymidine 
derivative turned out to be difficult to synthesize because of the facile formation of 
oxetanes.319 Compound 3320,321 and compound 4319 were synthesized according to 
previously reported protocols. The amino groups of compound 4 were 
trifluoroacetyl protected to avoid undesired Cu(II) complexation of the neomycin 
moiety during the click conjugation. 
 
Scheme 1.  (i) methyl[(pent-4-yn-1-yloxy)methyl]sulfide, NIS, CF3SO3H, THF, -40ºC, 2h; (ii) 
Bu4N+F–, THF, 2 h, rt; (iii) DMTrCl, pyridine, overnight, rt; (iv) 2-Cyanoethyl N,N-
diisopropylchlorophosphoramidite, Et3N, DCM, 2 h, rt; (v) CuSO4, sodium 
ascorbate, H2O, dioxane, dipropargyl ether, overnight, rt. 
3.1.1.2 Oligonucleotide synthesis 
For the synthesis of the neomycin-conjugated oligonucleotides ODN2–ODN7 and 
ODN9 (Figure 13), alkyne modified oligonucleotides were first synthesized on 
solid support on a 1.0 μmol scale using an automatic DNA/RNA synthesizer 
(Scheme 2). The phosphoramidite building blocks 1–3 were introduced into the 
oligonucleotides using the standard phosphoramidite coupling cycle. The coupling 
yields of the building blocks 1–3 were >97%, comparable to commercial 
phosphoramidites. After the oligonucleotide synthesis, the azide-derived neomycin 
(4) was coupled to the solid-supported oligonucleotides using the click chemistry 
conditions: 10 equivalents of 4, CuSO4/TBTA, sodium ascorbate, overnight at 
room temperature. The neomycin-conjugated oligonucleotides were then released 
from the solid support by concentrated ammonia (overnight at 55 °C), purified by 
RP HPLC and lyophilized to white powders of ODN2–ODN7 and ODN9 in 20–
Results and Discussion 
 41 
30% isolated yields. The authenticity of the oligonucleotides was verified by 
electrospray ionization time-of-flight mass spectrometry (ESI-TOF MS). The 
fluorine-labeled oligonucleotides were synthesized by introducing the 
phosphoramidite building block of 4’-C-[(4-CF3-1H-1,2,3- triazol-1-
yl)methyl]thymidine (F1, Figure 13) into the oligonucleotides as previously 
described by our group.316 
 
Scheme 2.  (i) 4, TBTA, CuSO4, sodium ascorbate, H2O, DMSO, 2-butanol, overnight at rt, (ii) 
conc. aq ammonia, overnight at 55 ºC. 
3.1.2 UV thermal melting studies 
The UV thermal melting temperatures (Figure 15, Table 1) were determined at pH 
5.5 and 6.0 by using 2.0 μmol L–1 or 1.0 μmol L–1 (entries 18–20) oligonucleotide 
concentration in 10 mmol L–1 sodium cacodylate and 0.1 or 0.3 mol L–1 NaCl in 
H2O. The triplex stability was higher at pH 5.5 compared to pH 6.0 as expected 
because of the protonation of the cytosine bases in the triplex-forming strand. At 
pH 5.5, the melting curves of the duplexes and triplexes overlapped in most cases 
when λ = 260 nm was used as the detection wavelength. By using λ = 295 nm as 
the detection wavelength, on the other hand, the unwinding of the C+*G-C triplet 
could be specifically monitored, and the triplex Tm values could be determined.277 
The influence of the conjugation site of the neomycin moiety on the triplex 
stability was first studied by comparing the Tm values of duplex 1 + ODN1–4 
(entries 1–4). The neomycin moiety was conjugated either to the C-5 site (ODN2), 
C-2’ site (ODN3) or C-4’ site (ODN4) of the thymidine residue. The C-5 conjugate 
ODN2 increased the triplex melting temperature by = +7.3 °C (pH 5.5) and +7.7 
°C (pH 6.0), while the C-2’ and C-4’ conjugates (ODN3 and ODN4) showed no 
effect. The importance of the conjugation site on the triplex stability is 
understandable, since the C-5 site is oriented toward the Watson–Hoogsteen 
groove, where the binding of neomycin takes place.115 The C-2’ and C-4’ sites, on 
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the other hand, are oriented outward from the triple helix, thus not providing 
favorable binding position for neomycin.  
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Figure 15.  Normalized UV melting profiles of duplex 1 + ODN1/ODN2/ODN7 at pH = 5.5 and 
6.0. Green curves: duplex 1 + ODN1, blue curves: duplex 1 + ODN2, dark blue 
curves: duplex 1 + ODN7. Detection wavelength: 260 nm (positive curves) or 295 
nm (negative curves). Conditions: 2.0 μmol L–1 of each oligonucleotide, 10 mmol L–
1 sodium cacodylate, 0.1 mol L–1 NaCl in H2O. 
The influence of the position of neomycin within the TFO sequence was evaluated 
by comparing the binding affinity of ODN2, ODN5 and ODN6, where the C-5 
neomycin conjugate was placed at different sites within the TFO. ODN2 and 
ODN5 provided almost equal stabilization (pH 5.5: ∆Tm3 = +7.3 °C vs. +8.1 °C; 
pH 6.0: ∆Tm3 = +7.7 °C vs. +7.5 °C, entries 2 and 5). Surprisingly, ODN6 showed 
no effect on the triplex stability (entry 6). In ODN6, the neomycin moiety was 
conjugated closer to the TFO terminus compared to ODN2 and ODN5, but this 
hardly explains the reduced stability. ODN6 and ODN2 have the same adjacent 
triplets (TAT-TAX-CGC), so they cannot play a role, either. The reason for the 
reduced binding affinity of ODN6 compared to ODN2 and ODN5 remained 
unresolved. 
When duplex 1 was targeted with ODN2, the neomycin-conjugated X*A-T 
triplet was next to T*A-T and C+*G-C triplets. To study if the neighboring triplets 
affect the binding affinity of the neomycin-conjugated TFOs, the binding of ODN9 
to duplex 3 was next evaluated. In the case of ODN9 + duplex 3, the X*A-T triplet 
is neighbored by two T*A-T triplets. This replacement of the C+*G-C triplet with 
T*A-T triplet decreased the stabilizing effect by 4.7 °C at pH 6.0 (∆Tm3 = +3.0 °C 
vs. +7.7 °C, entry 13 vs. 2, column C), but at pH 5.5, the decrease was marginal 
(∆Tm3 = +6.4 °C vs. +7.1 °C, entry 13 vs. 2, column F). 
To evaluate whether the neomycin-conjugated TFOs can stabilize the triplex 
also over a Hoogsteen mismatch, the binding of TFOs to duplex 2 was studied. 
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Duplex 2 contains one thymidine interruption (T vs. A, cf. duplex 1). At pH 6.0, 
ODN2 showed no stabilization, whereas at pH 5.5, ODN2 stabilized the triplex by 
+4.8 °C (entry 9). ODN5, on the other hand, stabilized the triplex almost equally 
with duplex 2 and duplex 1 at pH 5.5 (+8.2 °C vs. +8.1 °C, entry 10 vs. entry 5). 
This equal stabilization was expected, because the neomycin conjugation site in 
ODN5 is far from the mismatch region. 
Table 1.  UV thermal melting temperatures of the duplexes and triplexes. 
Entry        Triplex A B C D E F 
pH 5.5, 0.1 mol L-1 NaCl pH 6.0, 0.1 mol L-1 NaCl 
Tm
2 
(260nm)/ºC 
Tm
3 
(295nm)/ºC 
∆Tm
3 
(295nm)/ºC 
Tm
2 
(260nm)/ºC 
Tm
3 
(295nm)/ºC 
∆Tm
3 
(295nm)/ºC 
1 duplex 1 + ODN1 51.7 (± 0.4) 41.3 (± 0.7) – 53.0 (± 0.2) 28.7 (± 0.3)  – 
2 duplex 1 + ODN2 51.2 (± 0.0) 48.6 (± 0.0) +7.3a 52.2 (± 0.1) 36.4 (± 0.1) +7.7 a 
3 duplex 1 + ODN3 50.6 (± 0.1) 41.7 (± 0.0) +0.4 a 53.5 (± 0.1) 29.2 (± 0.3) +0.5 a 
4 duplex 1 + ODN4 50.1 (± 0.3) 41.4 (± 0.4) +0.1 a 53.5 (± 0.2) 27.4 (± 0.3) -1.3 a 
5 duplex 1 + ODN5 51.3 (± 0.0) 49.4 (± 0.6) +8.1 a 53.4 (± 0.3) 36.2 (± 0.1) +7.5 a 
6 duplex 1 + ODN6 51.3 (± 0.4) 41.4 (± 0.1) +0.1 a 53.8 (± 0.1) 27.8 (± 0.1) -0.9 a 
7 duplex 1 + ODN7 n.d. 57.1 (± 0.2) +15.8 a 51.3 (± 0.2) 44.3 (± 0.6) +15.6 a 
8 duplex 2 + ODN1 52.6 (± 0.3) 25.1 (± 0.1) – 54.1 (± 0.1) 14.9 (± 0.0) – 
9 duplex 2 + ODN2 53.1 (± 0.3) 29.9 (± 0.3) +4.8b 54.2 (± 0.2) 15.1 (± 0.0) +0.2b 
10 duplex 2 + ODN5 53.1 (± 0.1) 33.2 (± 0.3) +8.2b 54.7 (± 0.1) 17.4 (± 0.1) +2.3b 
11 duplex 2 + ODN7 52.2 (± 0.3) 40.8 (± 0.2) +15.7b 54.3 (± 0.1) 24.1 (± 0.4) +9.2b 
12 duplex 3 + ODN8 45.6 (± 1.1) 40.3 (± 0.2) – 50.6 (± 0.2) 30.6 (± 0.1) – 
13 duplex 3 + ODN9 48.3 (± 0.3) 46.7 (± 0.3) +6.4c 50.5 (± 0.1) 33.6 (± 0.1) +3.0c 
14 19F-duplex1 + 
ODN1 
n.d. 41.8 (± 0.1) +0.5a 53.5 (± 0.4) 29.3 (± 0.0) +0.6a 
15 19F-duplex2 + 
ODN1 
50.5 (± 0.0) 41.4 (± 0.1) +0.1a 53.2 (± 0.2) 28.3 (± 0.0) -0.5a 
16 19F-duplex2 + 
ODN2 
49.6 (± 0.3)  48.4 (± 0.2) -0.2d 52.6 (± 0.1) 34.3 (± 0.2) -2.1d 
17 19F-duplex3 + 
ODN1 
n.d. 40.6 (± 0.1) -0.7a 54.0 (± 0.1) 28.0 (± 0.0) -0.7a 
Entry        Triplex pH 5.5, 0.3 mol L-1 NaCl pH 6.0, 0.3 mol L-1 NaCl 
18 duplex 1 + ODN1 57.7 (± 0.2) 40.7 (± 0.2)  – 58.3 (± 0.5) 28.7 (± 0.1) – 
19 duplex 1 + ODN2 57.2 (± 0.3) 45.6 (± 0.0) +4.9e 57.5 (± 0.1) 33.1 (± 0.5) +4.4e 
20 duplex 1 + ODN7 56.4 (± 0.3) 50.9 (± 1.3) +10.2e 57.0 (± 0.2) 41.9 (± 0.5) +13.2e 
Conditions: 2 μmol L–1 solution of each oligonucleotide (entries 18–20: 1 μmol L–1), 10 mmol L–1 
sodium cacodylate. Notes: ∆Tm3 values compared to aduplex 1 + ODN1 in 0.1 mol L–1 NaCl, 
bduplex 2 + ODN1, cduplex 3 + ODN8, dduplex 1 + ODN2 and eduplex 1 + ODN1 in 0.3 mol L–1 
NaCl; n.d: Tm2 and Tm3 values could not be distinguished because of the overlapped duplex/triplex 
melting curves. 
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Finally, the binding of ODN7, containing two neomycin units, to duplex 1 and 
duplex 2 was studied. With duplex 1, the melting temperature was increased by 
+15.8 °C at pH 5.5 and +15.6 °C at pH 6.0 (entry 7). With duplex 2, the melting 
temperature was increased by +15.7 °C at pH 5.5 and +9.2 °C at pH 6.0 (entry 11). 
It may be worth noting that at pH 5.5, the melting temperature of ODN7 + duplex 1 
was even higher than the melting temperature of duplex 1 (57.1 °C vs. 51.7 °C, 
entry 7 vs. entry 1). In this case, the neomycin ligands hold all three sequences 
together, and the triplex is denaturated directly into single strands upon heating. 
Interestingly, while one neomycin unit at a Hoogsteen mismatch site (ODN2 + 
duplex 2) could not stabilize the triplex at pH 6.0 (entry 9, column F), the same 
conjugation site in ODN7 gave stabilization (cf. ∆Tm3 values of ODN7: +9.2 °C 
and ODN5: +2.3 °C, entries 11 and 10, column F). In conclusion, the increased 
overall triplex stability seemed to facilitate the neomycin-promoted triplex 
stabilization in the mismatch region. The same phenomenon can be observed by 
comparing the ∆Tm3 values of ODN2 + duplex 2 at pH 5.5 and 6.0: +4.8 vs. +0.2 
°C (entry 9).  
The triplex formation in the present study requires slightly acidic conditions, 
because the triplex model used in this study contains nine C+*G–C triplets. The 
C+*G–C triplet requires protonation at the N3 site of cytosine (pKa=4.5), and 
hence, the triplex formation remains marginal at neutral pH. Although the triplex 
melting temperatures are lower at pH 6.0 than at pH 5.5, ODN7 increased the 
melting temperature equally at pH 5.5. and 6.0 (∆Tm3 = +15.8 °C and +15.6 °C, 
entry 7). Previous studies with discrete neomycin have shown that the triplex-
stabilizing effect of neomycin decreases when the pH is increased from 7.2 to 8.1, 
as the pH approaches the pKa values of the neomycin amines, but neomycin is still 
effective at pH 8.1.115,125,126,134 
The triplex melting temperatures discussed above were obtained in a relatively 
low 0.1 mol L–1 salt concentration. The Tm3 values with different TFOs are 
comparable to each other, but the stabilizing effect of the polycationic neomycin 
unit may be overemphasized in low salt concentrations. Previous studies with a 
similar triplex model at pH 5.5 and 0.3 mol L–1 NaCl have shown that simple C-5-
(1-propargylamino) (see Figure 2), C-5-hydroxyprop-1-ynyl and C-5-prop-1-ynyl 
modifications already affect the triplex stability by ∆Tm3 = +4.6, +2.6 and –1.4 °C, 
and two modifications increased the triplex melting temperature by ∆Tm3 = +7.6, 
+5.3 and +3.2 °C, respectively.69 To evaluate how the salt concentration affects the 
binding affinity of the neomycin-conjugated TFOs, the Tm3 values of duplex 1 + 
ODN1, ODN2 and ODN7 were determined also in 0.3 mol L–1 NaCl 
concentration. The ∆Tm3 values were lower compared to those in 0.1 mol L–1 NaCl: 
+5.0 °C (pH 5.5) and +4.4 °C (pH 6.0) with ODN2 (entry 19) and +10.4 °C (pH 
5.5) and +13.2 °C (pH 6.0) with ODN7 (entry 20). Although part of the triplex 
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stabilization obtained by the neomycin units may result from the C-5 spacer alone, 
the ∆Tm3 values with two neomycin units (ODN7) were remarkable. 
3.1.3 19F NMR studies 
To monitor the thermal unwinding of the triplexes in more detail, 19F NMR 
spectroscopy was used. 4’-C-[(4-CF3-1H-1,2,3-triazol-1-yl)methyl]thymidine316 
(F1, Figure 13) was inserted into three different sites of duplex 1 (19F-duplex 1–3, 
Figure 13) and the triplex/duplex/single strand conversion was monitored by 19F 
NMR spectroscopy. The F1 sensor was previously developed in our laboratory.316 
The 19F resonance shift of the sensor was highly sensitive to environmental 
changes in the secondary structures of oligonucleotides, and the sensor caused no 
effect on the DNA triplex stabilities.  
In the present study, the 19F NMR spectroscopic measurements were performed 
in solutions of 50 μmol L–1 of each oligonucleotide, 10 mmol L–1 sodium 
cacodylate (pH 5.5 or 6.0) and 0.1 mol L–1 NaCl in D2O/H2O (1:9, v/v). According 
to the UV and CD spectroscopic thermal melting profiles, 19F-duplex 1–3 + ODN1 
all had equal thermal stability (Table 1, entries 14, 15 and 17). However, the 
behavior of the 19F NMR resonance signals showed notable differences depending 
on the 19F labeling site. 19F-duplex 2 + ODN1 and 19F-duplex 3 + ODN1 behaved 
in a very similar manner (Figure 16 b and c). In both cases, when 1.0 equivalent of 
ODN1 was added to the 19F-labeled duplex, the 19F resonance signal of the duplex 
was fully replaced by a signal resulting from the triplex (at 30 °C, signals at 61.93 
ppm and 62.17 ppm). When the temperature was increased, the signal of the triplex 
was gradually converted into the signal of the duplex and ultimately to the signal of 
the single strand. According to the relative peak areas of the 19F resonance signals, 
the molar fractions of triplex, duplex and single strand could be determined at each 
temperature.  
19F-duplex 1 + ODN1, on the other hand, behaved in drastically different 
manner compared to 19F-duplexes 2–3. The addition of 1.0 equivalent of ODN1 to 
19F-duplex 1 gave two relatively broad signals in 1:3 ratio (n/n) at 30 °C (Figure 16 
a, 61.80 ppm and 62.07 ppm). Moreover, when the temperature was increased, the 
duplex signal appeared very close to the larger triplex signal. In the case of 19F 
duplexes 2–3, by contrast, the triplex and duplex signals were clearly 
distinguishable. Complete explanation for the different behavior of 19F-duplex 1 
remained unknown. Previous studies that used the same triplex sequence suggested 
that an i-motif (or unspecific C+*C base pairing) competes with the triplex 
formation.315 Interestingly, the 19F label in 19F-duplex 1 is in the same region as the 
C-5 neomycin conjugate in ODN6, the only C-5 neomycin modified TFO that was 
unable to stabilize the triplex (duplex 1 + ODN6, Table 1, entry 6). It is noteworthy 
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that all three 19F-duplexes with ODN1 gave nearly identical UV and CD thermal 
melting profiles and triplex melting temperatures. Therefore, the different 19F NMR 
spectra of 19F-duplexes 1–3 + ODN1 illustrated different local environments in the 
triplex model. The modest binding affinity of ODN6 may result from a twisted 
groove environment at the neomycin conjugation site. 
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Figure 16.  19F NMR spectra of 19F-duplex 1–3 + ODN1 at 30–50 °C (a–c), CD spectra at 
different temperatures (d–f) and UV thermal melting profiles at λ = 295 nm (h) from 
the same mixtures. CD spectra of 19F-duplex 2 + ODN2 (g) are also included in 
comparison to e. 
Next, the binding of neomycin-conjugated ODN2 to 19F-duplex 2 was monitored 
by 19F NMR spectroscopy at pH 5.5 and 6.0. The 19F NMR spectra of 19F-duplex 2 
+ ODN1 and ODN2 at different temperatures are shown in Figure 17 and the 
corresponding relative peak areas of the 19F resonance signals as a function of 
temperature in Figure 18 a and b. In addition to the signals of triplex, duplex and 
single strand, small additional signals were also observed, probably related to 
minor secondary structures or aggregation. However, the relative peak areas could 
be adequately integrated. At pH 5.5, both ODN1 and ODN2 were fully Hoogsteen-
hybridized, when the temperature was lower than 30 °C (Figure 18a). The 19F 
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NMR based triplex denaturation curve for 19F-duplex 2 + ODN2 showed two 
inflection points (Figure 18a), whereas the UV thermal melting profile from the 
same mixture showed only one inflection point (Figure 18c). The latter inflection 
point of the 19F NMR based triplex denaturation curve was close to the UV based 
Tm3 value (ca. 58 °C, note the 25-fold oligonucleotide concentrations compared to 
the Tm3 values in Table 1). According to the 19F NMR measurements, this Tm3 value 
resulted from the simultaneous denaturation of the Hoogsteen and Watson–Crick 
hydrogen bonds. Triplex was the predominant secondary structure throughout the 
whole denaturation range, 40–60 °C, although notable amount of duplex was also 
present at temperatures 45–57.5 °C. 
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Figure 17.  Triplex/duplex/single strand conversion of 19F-duplex 2 + ODN1 vs. ODN2 followed 
by 19F NMR spectroscopy. Conditions: 50 μmol L–1 of each oligonucleotide, 
10 mmol L–1 sodium cacodylate (pH 5.5 or 6.0), 0.1 mol L–1 NaCl in D2O/H2O (1:9, 
v/v).  
At pH 6.0, on the other hand, the triplex was not formed quantitatively after 1.0 
equivalent of ODN1 and ODN2 was added to 19F-duplex 2, but the molar fraction 
of the triplex was ca. 55% and 65% with ODN1 and ODN2, respectively (Figure 
18b). Duplex became the predominant secondary structure at temperatures over 25 
°C with ODN1 and at temperatures over 30 ° with ODN2. The molar fractions of 
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different secondary structures remain hidden in UV and CD spectrophotometric 
data. Therefore, at the spectrophotometry based melting points (Tm), the 
equilibrium constant K may be far from the general definition: K = Cinit/2, where 
Cinit = initial oligonucleotide concentration. For example, at the inflection points of 
the triplex melting curves at pH 6.0 (Tm3, Figure 18b), the molar fraction of the 
duplex is much higher than the molar fraction of the triplex, and thus, K < Cinit/2. 
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Figure 18.  a–b) The relative molar fractions of triplexes, duplexes and single strands upon 
thermal denaturation obtained by 19F NMR spectroscopy (19F-duplex 2 + ODN1 vs. 
ODN2, cf. Figure 17). c) The normalized UV melting profiles of the 19F NMR 
samples. Conditions: 50 μmol L–1 of each oligonucleotide, 10 mmol L–1 sodium 
cacodylate (pH 5.5 or 6.0), 0.1 mol L–1 NaCl in D2O/H2O (1:9, v/v). 
3.2 Recognition of the nucleobase content in the 
target DNA duplex by 19F-labeled TFO probes 
In the second section of this thesis, 19F-labeled TFO sensors capable of recognizing 
variable nucleobases in the pyrimidine strand of the target DNA duplex were 
developed (ONF 1–3, Figure 19). Before this study, no reliable method for sensing 
the pyrimidine strand in double-helical DNA was reported. For the synthesis of 
ONF 1–3, phosphoramidite building blocks of F1–3 (Figure 19a) were synthesized 
and incorporated into the TFOs by automated DNA synthesis. Sensors F2 and F3 
are CF3 analogs of a previously reported triplet-forming nucleobase modification 
2’-deoxy-N4-(6-aminopyridin-2-yl)cytidine,322 whereas sensor F1 was previously 
developed in our laboratory.316 The TFO probes ONF1–3 were targeted to the 
purine strand of the target duplex (ODN11 and ODN12), and the nucleobase 
content in the pyrimidine stand of the target duplex was varied (ODN10, X = T, A, 
C or G).  ONF 1–3 were expected to give different 19F NMR shifts depending on 
the variable nucleobases in the target duplex. In the case of ONF1, the plausible 
19F NMR shift discrimination was expected to be based on the changes in the local 
environment of the Watson–Hoogsteen groove. ONF 2–3, on the other hand, were 
expected to recognize the whole base pair more specifically (Figure 19b). The 19F 
NMR shift of sensors 2 and 3 was assumed to be dependent on the spatial 
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orientation of the CF3 group, the possible existence or absence of the extra 
hydrogen bonds, intercalation in the triplet and potential changes in the steric 
environment when the nucleobases in the target duplex were varied. 
 
Figure 19.  a) The principle of the 19F-labeled TFO probes and the structures of sensors F1–3. 
b) The triple-helical models and the proposed hydrogen bonding of sensors F2 and 
F3 including tautomers and rotamers. 
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3.2.1 Synthesis of the 19F-labeled TFO probes 
3.2.1.1 Synthesis of the Phosphoramidite Building Blocks of Sensors F2 
and F3 
The synthesis of the phosphoramidites 10 and 11 is presented in Scheme 3. The 
previously reported322 4-triazolyl-2’-deoxyuridine (12) was first exposed to 
transamination with 2,2-diaminopyridines to yield compounds 13 and 14. 
Compound 13 was then protected with benzoyl chloride to give compound 15 and 
compound 14 was protected with 4-trifluoromethylbenzoic acid to give compound 
18. The 3’- and 5’-O-acetyl groups were selectively removed with a gentle 
treatment with ammonia and the 5’-OH group was 4,4’-dimethoxytritylated to give 
17 and 20. Finally, the 3’-OH group was phosphitylated with 2-cyanoethyl N,N-
diisopropylphosphoramidochloridite to give phosphoramidites 10 and 11. 
 
Scheme 3. (i) 4-trifluoromethyl-2,6-diaminopyridine in Py for 13 and 2,6-diaminopyridine in Py 
for 14; (ii) Benzoyl chloride in Py for 15 and 4-trifluoromethylbenzoic acid, PyBOP, 
DIEA, DMF for 18; (iii) NH3 (aq), methanol; (iv) DMTrCl in Py; (v) 2-Cyanoethyl 
N,N-diisopropylchlorophosphoramidite, Et3N, DCM. 
3.2.1.2 Oligonucleotide synthesis 
The 19F-labeled oligonucleotide probes ONF1–ONF3 were synthesized on solid 
support on a 1.0 μmol scale using an automatic DNA/RNA synthesizer. ONF1 was 
synthesized by introducing the phosphoramidite building block of 4’-C-[(4-CF3-
1H-1,2,3- triazol-1-yl)methyl]thymidine (F1) as described previously by our 
group.316 ONF2 was synthesized on a standard dC-3’-O-yl succinate loaded 
LCAA-CPG support and ONF3 on a dC-3’-O-yl hydroquinone O,O-diacetate (“Q-
linker”) loaded LCAA-CPG support. The phosphoramidite building blocks 10 and 
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11 were introduced into the oligonucleotides using coupling time of 600s. The 
coupling yields of the building blocks 10 and 11 were > 97%, comparable to 
commercial phosphoramidites. After the oligonucleotide synthesis, ONF2 was 
released from the solid support by concentrated ammonia (overnight at 55 °C) and 
ONF3 by 0.05 M K2CO3 in methanol. This gentle release from the Q-linker leaved 
the 4-trifluoromethylbenzoyl group of ONF3 intact. On the other hand, the benzoyl 
protection of the 4-trifluoromethyl-2,6-diaminopyridine moiety of ONF2 was 
surprisingly stable. To remove the benzoyl protection, ONF2 was, after cleavage 
from the solid support, further treated with a mixture of 40% aqueous methylamine 
and concentrated ammonia (1:1, v/v, 5 h at 55 °C). Finally, ONF2 and ONF3 were 
purified by RP HPLC and lyophilized into white powders. The authenticity of the 
oligonucleotides was verified by MS (ESI-TOF) spectroscopy. According to UV 
absorbance at 260 nm, the isolated yields of ONF2 and ONF3 were 18% and 25%, 
respectively. 
3.2.2 UV thermal melting studies  
First, the effect of the sensors F1–3 on the thermal stability of the triplexes 
(ODN10/ODN11/ONF1–3 and ODN10/ODN12/ONF2–3) was studied by UV 
melting profile analysis. Sensors F2 and F3 are CF3 analogs of previously reported 
2’-deoxy-N4-(6-aminopyridin-2-yl)cytidine322 that was originally designed for the 
recognition of the C–G base pair interruption in the purine strand of dsDNA target. 
However, binding to A–T and, to a smaller extent, to G–C base pairs was also 
reported. Therefore, sensors F2 and F3 were expected to recognize A–T and G–C 
base pairs, depending on the tautomers (cf. Figure 19b). In the 
ODN10/ODN11/ONF1–3 triplexes, sensors F1–3 were aimed to bind to the 
adenine residue of ODN11, and in the ODN10/ODN12/ONF2–3 triplexes, sensors 
F2 and F3 were aimed to bind to the guanine residue of ODN12. The UV thermal 
melting temperatures of the triplexes were determined at pH 5.5 using 2.0 μmol L–1 
oligonucleotide concentration in 10 mmol L–1 sodium cacodylate and 0.1 mol L–1 
NaCl in H2O, detection wavelength λ = 260 nm and 295 nm. The ∆Tm3 values given 
in parentheses are those compared to the Tm3 values of the unmodified triplexes 
ODN10/ODN11/ODN13 and ODN10/ODN12/ODN14. 
As seen in Table 2, sensor F1 (ONF1) reduced the triplex stability to a small 
extent (∆Tm3 = -2.4 – -3.0°C compared to the unmodified ODN10/ODN11/ODN13 
triplex), whereas sensor F2 reduced the stability remarkably (∆Tm3 = -5.8 – -14.3°C 
compared to ODN10/ODN11/ODN13 triplex and ∆Tm3 = -9.6 – -16.8°C compared 
to ODN10/ODN12/ODN14 triplex). Sensor F3 also reduced the triplex stability in 
most cases (∆Tm3 = -3.6 – -7.2°C compared to ODN10/ODN11/ODN13 and ∆Tm3 
= -1.8 – -8.1°C compared to ODN10/ODN12/ODN14). Interestingly, in the case of 
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ODN10/ODN11/ONF3 with a F3*A-A triad (X = A in ON10), a small triplex 
stabilization was observed (∆Tm3 = +1.2°C). However, it may be concluded that 
sensors 2 and 3 are probably unable to bind through the optimal hydrogen bonding 
patterns suggested in Figure 19. It is worth noting that ONF2 and ONF3 single 
strands may exist as several tautomers and rotamers, but the triple-helical structure 
reduces the structural mobility. However, the rotation around the N4(Cyt)–C2(Py) 
σ-bond may be relatively easy, thus preventing the hydrogen bonding between the 
sensor and O4(Thy) (Figure 19b), for instance. Additionally, the protonation of the 
sensors, particularly the protonation of the pyridine residue, may play important 
role in the binding. Compared to sensor F2, sensor F3 caused less decrease in the 
triplex stability. It is possible that the 4-CF3-benzoyl moiety of F3 compensated the 
reduced triplex stability by intercalation. Sensors F2 and F3 showed no notable 
selectivity between binding to adenine and guanine bases. This observation 
supports the idea of the alternating tautomers of F2 and F3, although the triplex 
stability was decreased in both cases. 
Table 2.  UV thermal melting temperatures of the triplexes. 
duplex ODN13 ODN14 ONF1 ONF2 ONF3 
   Tm3 / °C   
ODN10/ODN11 
 
X = T 
X = A 
X = C 
X = G 
 
ODN10/ODN12 
 
X = T 
X = A 
X = C 
X = G 
 
 
40.8 ± 0.4 
36.3 ± 0.2 
37.9 ± 0.1 
36.9 ± 0.2 
 
 
 
 
 
 
 
 
 
40.1 ± 0.5 
40.3 ± 0.1 
42.5 ± 0.4 
38.8 ± 0.2 
 
 
38.4 ± 0.2 (–2.4) 
33.3 ± 0.3 (–3.0) 
34.9 ± 0.1 (–3.0) 
33.9 ± 0.3 (–3.0) 
 
 
26.5 ± 0.4 (–14.3) 
30.5 ± 0.3 (–5.8) 
25.2 ± 0.4 (–12.7) 
23.3 ± 0.6 (–13.6) 
 
 
 
29.6 ± 0.3 (–10.5) 
29.7 ± 0.2 (–10.6) 
25.7 ± 0.4 (–16.8) 
29.2 ± 0.2 (–9.6) 
 
 
33.6 ± 1.2 (–7.2) 
37.5 ± 0.5 (+1.2) 
32.3 ± 0.7 (–5.6) 
34.3 ± 1.2 (–3.6) 
 
 
 
36.3 ± 0.6 (–3.8) 
33.9 ± 0.5 (–6.4) 
34.4 ± 0.6 (–8.1) 
37.0 ± 0.6 (–1.8) 
Conditions: 2.0 μmol L–1 of each oligonucleotide, 10 mmol L–1 sodium cacodylate (pH 5.5), 0.1 
mol L–1 NaCl in H2O, detection wavelength 295 nm. Notes: ∆Tm3 values given in parentheses are 
those compared to the Tm3 values of the unmodified triplexes ODN10/ODN11/ODN13 and 
ODN10/ODN12/ODN14. 
3.2.3 19F NMR studies 
Next, the ability of sensors F1, F2 and F3 to recognize variable nucleobase content 
in the pyrimidine strand of the target duplexes was evaluated. The 19F NMR 
spectroscopic measurements were performed using 10 μmol L–1 oligonucleotide 
concentration in a mixture of 10 mmol L–1 sodium cacodylate (pH 5.5) and 
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0.1 mol L–1 NaCl in D2O/H2O (1:9, v/v) at 20 °C. First, the applicability of sensor 
F1 (ONF1) was examined (Figure 20a). ONF1 single strand gave a relatively 
sharp 19F resonance signal at –62.73 ppm. When 1 equivalent of the purine strand 
ODN11 was added, the original signal was replaced by several scattered signals, 
indicating unspecific interactions between ONF1 and ODN11. Adding 1 
equivalent of the pyrimidine strand ODN10 resulted in one, relatively sharp 19F 
resonance signal. With the complementary ODN10/ODN11/ONF1 triplex (X = T 
in ODN10, forming a F1*A-T triplet), the chemical shift of this signal was –61.87 
ppm. The non-matching F1*A-C triplet (X = C in ODN10) gave a signal at exactly 
the same chemical shift. The F1*A-A triplet (X = A in ODN10) gave a signal with 
a slightly different chemical shift (–61.83 ppm), whereas in the case of the F1*A-G 
triplet (X = G in ODN10), the change in the chemical shift was notable (–61.54 
ppm). Taken together, sensor F1 was able to discriminate the adenine-pyrimidine 
base pairs (A-T and A-C) from adenine-purine base pairs (A-A and A-G), although 
the discrimination between the A-A base pair and adenine-pyrimidine base pairs 
was modest. 
Next, the same measurements were performed with sensors F2 and F3 (ONF2 
and ONF3), which were expected to recognize the variable nucleobase content 
more specifically. ONF2 single strand gave a 19F resonance signal at –65.11 ppm 
(Figure 20b). This signal was considerably broader compared to ONF1. When 1 
equivalent of ODN11 was added, a new broad signal at –64.70 ppm was observed. 
Adding 1 equivalent of ODN10 resulted in a unique chemical shift for each 
ODN10/ODN11/ONF2 triplex (X = T, A, C or G in ODN10). All the signals 
were relatively broad. However, all the signals could be distinguished from a 
mixture containing all the four ODN10/ODN11/ONF2 triplexes (X = T, A, C or 
G in ODN10; see Figure 22a), although the signals of F2*A-A and F2*A-G 
overlapped partially. 
ONF3 single strand gave two distinct 19F resonance signals, major one at 
–62.68 ppm and minor one at –62.20 ppm (Figure 20c). The distinct signals 
most likely originate from rotamers of F3. The addition of the duplex 
ODN10/ODN11 resulted in unique signals with the F3*A-T triplet, with the 
F3*A-A triplet and with the F3*A-C triplet, but the F3*A-A triplet and the 
F3*A-G triplet gave the same chemical shift. In other words, sensor F3 was 
unable to discriminate purine bases from each other. The 19F NMR spectrum 
of a mixture containing all the four ODN10/ODN11/ONF3 triplexes (X = T, 
A, C or G in ODN10) is shown in Figure 22b. 
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Figure 20.  19F NMR spectra of the ODN10/ODN11/ONF1–3 triplexes (F*A-X triplets, X = T, A, 
C or G). Conditions: 10 μmol L–1 of each ON, 10 mmol L–1 sodium cacodylate (pH 
5.5), 0.1 mol L–1 NaCl in D2O/H2O (1:9, v/v) at 20 °C. 
 
3'-CCT TCC TXC TCC CTC-5'   ODN10, X = T, A, C or G
5'-GGA AGG AAG AGG GAG-3' ODN11
5'-CCT TCC TFC TCC CTC-3' ONF1-3
ONF1: -62.73 ppm
ONF1 + ODN11
ONF1 + ODN11 + ODN10
X = T: -61.87 ppm
X = A: -61.83 ppm
X = C: -61.87 ppm
X = G: -61.54 ppm
X = T: -62.38 ppm (+ minor at -62.11 ppm)
X = A: -62.13 ppm
X = C: -62.33 ppm
X = G: -62.13 ppm
ONF3 + ODN11 + ODN10
ONF3: -62.68 ppm (+ minor at -62.60 ppm)
ONF3 + ODN11: -62.59 ppm
-60.5            -61.0             -61.5             -62.0             -62.5             -63.0              -63.5              -64.0 ppmδ
X = T: -66.09 ppm
X = A: -67.27 ppm
X = C: -66.33 ppm
X = G: -67.10 ppm
ONF2 + ODN11 + ODN10
ONF2: -65.11 ppm
ONF2 + ODN11: -64.70 ppm
ONF1: F = F1
ONF2: F = F2
ONF3: F = F3
-64.4            -64.9            -65.5            -65.9              -66.4             -66.9               -67.4              -67.9 ppmδ
-60.5            -61.0             -61.5             -62.0             -62.5             -63.0              -63.5              -64.0 ppmδ
a)
b)
c)
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Figure 21. 19F NMR spectra of the ODN10/ODN12/ONF2–3 triplexes (F*G-X triplets, X = T, A, 
C or G). Conditions: 10 μmol L–1 of each ON, 10 mmol L–1 sodium cacodylate (pH 
5.5), 0.1 mol L–1 NaCl in D2O/H2O (1:9, v/v) at 20 °C. 
Depending on the tautomers, sensors F2 and F3 may also bind to the guanine base 
in the target duplex. Therefore, the ability of ONF2 and ONF3 to recognize 
variable nucleobase content in ODN10/ODN12 duplex (X = T, A, C or G in 
ODN10) was next studied (Figure 21). Interestingly, both ONF2 and ONF3 gave a 
relatively sharp 19F resonance signal after the addition of the purine strand ODN12. 
When ODN10 was added to the mixture of ONF2 and ODN12, unique chemical 
shifts were observed for each ODN10/ODN12/ONF2 triplex (Figure 21a). As 
seen, the F2*G-purine triplets gave one, relatively sharp signal, whereas the 
F2*G-pyrimidine triplets gave two resonance signals. Consequently, sensor 
F2 targeted to A-T and A-C base pairs may adopt two relatively stable 
 
3'-CCT TCC TXC TCC CTC-5'   ODN10, X = T, A, C or G
5'-GGA AGG AGG AGG GAG-3' ODN12
5'-CCT TCC TFC TCC CTC-3' ONF2 & 3
X = C: -62.12 ppm (minor at -62,27)
X = A: -62.26 ppm
X = T: -62.38 ppm
X = G: -61.79 ppm
ONF3 + ODN12 + ODN10
ONF3: -62.68 ppm (+ minor at -62.60 ppm)
ONF3 + ODN12: -62.54 ppm
-60.5            -61.0             -61.5             -62.0             -62.5             -63.0              -63.5              64.0 ppmδ
X = C: -66.08 ppm (+ minor at -66.25)
X = A: -64.40 ppm
X = T: -65.95 and -66.33 ppm
X = G: -66.49 ppm
ONF2 + ODN12 + ODN10
ONF2: -65.11 ppm
ONF2 + ODN12: -64.29 ppm
ONF2: F = F2
ONF3: F = F3
-63.7            -64.2            -64.7            -65.2               -65.7             -66.2              -66.7            67.2 ppmδ
a)
b)
Ville Tähtinen 
 56 
conformers, thus resulting in distinct signals. These split signals also 
disturbed the 19F NMR analysis of a mixture containing all the four 
ODN10/ODN12/ONF2 triplexes (Figure 22c). However, all the signals could be 
distinguished also from this mixture. 
Among these experiments, sensor F3 (ONF3) with ODN10/ODN12 duplex 
showed the best 19F NMR spectroscopic results. Unique chemical shifts were 
observed for each ODN10/ODN12/ONF3 triplex (Figure 21b). The signals could 
also be distinguished from a mixture containing all the four 
ODN10/ODN12/ONF3 triplexes (Figure 22d). When sensors F2 and F3 are 
compared to each other, the 4-trifluoromethylbenzoyl group of F3 seems to be 
beneficial for the recognition. The 2,6-diaminopyridine moiety of sensor F3 is 
probably prone to adopting alternative conformers, thus resulting in two distinct 19F 
resonance signals when targeted to G-pyrimidine base pairs. 
 
Figure 22. 19F NMR spectra of the mixtures of ODN10/ODN11/ONF2, ODN10/ODN11/ONF3, 
ODN10/ODN12/ONF2 and ODN10/ODN12/ONF3 triplexes. Conditions: 10 μmol L–
1 of each ON10, 40 μmol L–1 of ODN11, ODN12, ONF2 and ONF3, 10 mmol L–1 
sodium cacodylate (pH 5.5), 0.1 mol L–1 NaCl in D2O/H2O (1:9, v/v) at 20 °C. 
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3.3 Recognition of double-helical microRNA by 
TFPNAs 
In the third section of this thesis, 19F NMR spectroscopy was used to obtain new 
information on the different binding mechanisms by which triplex-forming PNAs 
(PNAs 1–10, Figure 23) bind to double-stranded regions of RNA hairpins. For this 
purpose, 19F sensors, previously developed in our laboratory, were incorporated to 
two target RNA hairpins, an AU-rich duplex with a hexaethylene glycol loop and a 
biologically relevant miR-215 model (ONR1 and ORN2, Figure 23). The 19F NMR 
spectroscopic analysis revealed detailed information on the stoichiometry and 
transition between two alternative binding modes, 1:1 PNA/RNA triplex and 2:1 
(PNA)2/RNA triplex invasion complex. Moreover, aiming to enhance the binding 
affinity and selectivity for 1:1 PNA/RNA triplex formation, chiral γ-(R)-
hydroxymethyl and γ-(S)-guanidinylmethyl modifications were introduced to the 
TFPNAs (PNAs 2, 3 and 5–9, Figure 23).  
 
Figure 23.  The RNA hairpin targets and the structures of the PNAs studied herein. 
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3.3.1 Synthesis of PNAs 
3.3.1.1 PNA monomers 
The modified PNA monomers 21–25 used for the synthesis of TFPNAs are outlined 
in Figure 24. 2-(6-Aminopyridin-3-yl)acetate (21) and 2-[(6-oxo-1,6-
dihydropyridazin-3-yl)amino]acetate (22) derived monomers were previously 
described by the groups of Rozners and Nielsen, but with different protecting 
groups.25,323 In the monomer 21, trityl (Trt) was used as protecting group for the N6 
side chain instead of tert-butyloxycarbonyl (Boc) that was applied in the report by 
Zengeya et al.25 Monomer 22 differs from the previously reported E monomers24,323 by 
its p-methoxybenzyl (PMB) protection, which increased the solubility in N-methyl-2-
pyrrolidone (NMP). The syntheses of 21–25 are presented in Scheme 4. For the 
synthesis of monomer 21, 2-(6-aminopyridin-3-yl)acetic acid (26) was N6-tritylated 
through trimethylsilyl ether (TMS) transient protection and coupled to 28.324 Finally, 
Pd0 catalyzed allyl group removal gave monomer 21 in 62% overall yield (from 26, 3 
steps). For the synthesis of monomer 22, compound 30 was converted into compound 
31 by nucleophilic aromatic substitution using p-methoxybenzyl alcoholate in p-
methoxybenzyl alcohol at elevated temperature. Compound 31 and compound 28 
were then coupled using BOP as coupling reagent, and Pd0 catalyzed allyl removal 
gave monomer 22 in 20 % overall yield (from 30, 3 steps).  
 
Figure 24.  Modified PNA building blocks 21–25 used for the synthesis of TFPNAs. 
For the synthesis of the γ-(R)-tert-butyloxymethyl modified monomers 23 and 24, 
allyl N-[(R)-3-tert-butoxy-N2-Fmoc-2-aminoprop-1-yl]glycinate (35) was 
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synthesized by reductive amination between freshly prepared (S)-2-amino-3-
hydroxypropanal (33, “(S)-N-Fmoc-O-tBu-serinaldehyde”) and allyl glycinate (34). 
The optical purity of 35 was confirmed by chiral HPLC analysis. Thereafter, 
compound 35 was coupled with either thymine-1-yl acetic acid or 2-[6-
(tritylamino)pyridine-3-yl]acetic acid (27) using BOP as coupling reagent, and 
finally Pd0 catalyzed allyl removal gave monomers 23 and 24 in 32 and 47 % 
overall yields, respectively (from 35, 3 steps). For the synthesis of the γ-(R)-
azidomethyl modified monomer 25, compound 39 was first synthesized from the 
Weinreb amide 38325 by reduction with LiAlH4, and reductive amination between 
freshly prepared 39 and allyl glycinate (34) then yielded compound 40. The optical 
purity of 40 was confirmed by chiral HPLC analysis. Thereafter, compound 40 and 
thymine-1-yl acetic acid were coupled using BOP as coupling reagent, and finally 
Pd0 catalyzed allyl removal gave the monomer 25 in 9 % overall yield (from 38, 4 
steps). All the monomers 21–25 were readily soluble in NMP to provide 
0.25 mol L–1 solutions needed for the peptide synthesizer. 
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Scheme 4.  (i) 1) Me3SiCl, Py; 2) TrtCl, Py; 3) H2O; (ii) BOP, DIEA, DMF; (iii) [Pd(PPh3)4], 
phenylsilane, THF; (iv) NaH, p-methoxybenzyl alcohol; (v) NaBH3CN, 
AcOH/MeOH (1:99 v/v); (vi) thymine-1-yl acetic acid or 2-[6-(tritylamino)pyridine-3-
yl]acetic acid (27), BOP, DIPEA, DMF; (vii) LiAlH4, THF. 
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3.3.1.2 Synthesis of TFPNAs and ORNs 
PNAs 1–10 (Figure 23) were synthesized on a 10 μmol scale by automated peptide 
synthesizer. PNA1 was previously described by Zengeya et al.25 In the PNA 
synthesis, the modified PNA monomers 21–25 and commercially available Fmoc-
PNA-T-OH and amino acid building blocks (Boc-Lys(Fmoc)-OH, Fmoc-Arg(Pbf)-
OH, Fmoc-Lys(Fmoc)-OH) were incorporated into the PNA sequences using 
Fmoc/t-Bu peptide synthesis cycle. After synthesis, the solid-supported PNAs were 
released with a mixture of anisole and trifluoroacetic acid (TFA), precipitated in 
Et2O and purified by RP HPLC. The homogeneity of the products was confirmed 
by RP HPLC, and the authenticity was verified by ESI-TOF MS.  
For the synthesis of γ-(S)-guanidinylmethyl modified PNAs 7–9, γ-(R)-
azidomethyl modified PNAs 7–9 (N3) were first synthesized by automated PNA 
synthesis (Scheme 5). The γ-(R)-azidomethyl groups were then reduced into γ-(S)-
aminomethyl groups and guanidinylated on solid support. The reduction step was 
carried out by treatment with Me3P and the guanidinylation step by treatment with 
1,3-di-Boc-2-(trifluoromethylsulfonyl)-guanidine. For the synthesis of the HiLyte 
Fluor 488 (HF488) labeled PNAs (HF488-PNA4 & HF488-PNAs 7–10, Figure 
23), two 2-(2-aminoethoxy)ethoxy acetic acid (AEEA) spacers were attached to the 
amino terminus of the PNAs and the HF488 label was coupled following a 
previously described procedure.326 More details on the PNA synthesis are described 
in the Experimental section. 
The RNA hairpin targets ORN1 and ORN2 (Figure 23) and the 19F-labeled 
oligoribonucleotides ORN3–8 were synthesized on a 1.0 μmol scale by automatic 
DNA/RNA synthesizer. The 19F probes were incorporated using 2’-O-[(4-CF3-
triazol-1-yl)methyl]uridine317 and -adenosine314 derived phosphoramidite building 
block as previously described. More details on the ORN synthesis are described in 
the original publications. 
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Scheme 5.  (i) Me3P, H2O/dioxane; (ii) 1,3-di-Boc-2-(trifluoromethylsulfonyl)-guanidine, Et3N, 
THF; (iii) anisole/TFA. 
3.3.2 19F NMR spectroscopic analysis of PNA/RNA triplexes 
3.3.2.1 PNA/heg hairpin triplexes 
The 19F NMR spectroscopic analysis was started by monitoring the thermal 
unwinding of the 19F-labeled RNA hairpin models ORN3 and ORN4 without PNA 
(Figure 25). ORN3 and ORN4 contain an AU-rich duplex region connected by a 
hexaethylene glycol (heg) loop. The 2’-O-[(4-CF3-triazol-1-yl)methyl]sensor was 
placed either in the middle of the pyrimidine strand (ORN3) or at the opposite site 
in the purine strand (ORN4). The 19F NMR spectroscopic measurements were 
performed by using an RNA concentration of 50 μmol L–1 in a mixture of 
10 mmol L–1 sodium cacodylate (pH 7.0) and 0.1 mol L–1 NaCl in D2O/H2O (1:9, 
v/v). Upon heating, both hairpins ORN3 and ORN4 gave a well-behaved 
coalescence signal (Figure 25 a & b). To determine the 19F NMR spectroscopy 
based thermal melting temperatures, the chemical shifts of these signals were 
presented as a function of temperature (after subtracting the passive temperature-
dependent shift 0.0135 ppm °C–1). The resulting melting profiles followed negative 
S curves, and the melting temperatures were determined based on the inflection 
points of the curves: (A/B, Figure 25; ORN3: Tm1 = 59.2 °C and ORN4: Tm1 = 
56.9 °C; Table 3). The 19F NMR spectroscopy based Tm values were consistent 
with the Tm values obtained by the UV melting profiles: 60.6 °C, 58.7 °C and 57.1 
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°C for ORN1, ORN3 and ORN4, respectively (Table 6). Accordingly, the 2’-O-
[(4-CF3-triazol-1-yl)methyl]sensor destabilized the hairpin to some extent, and the 
destabilizing effect was higher in the purine strand than in the pyrimidine strand 
(ORN3 vs. ORN4, ∆Tm = –1.9 °C vs. –3.5 °C).  
Next, the applicability of 19F NMR spectroscopy for the detection of 
PNA/RNA triplexes was evaluated. PNAs 1–3 (Figure 23) were designed for 
targeting the RNA hairpin model ORN1 (and the corresponding 19F-labeled ORN3 
and ORN4). PNAs 1–3 are decamers containing eight thymine and two 2-
aminopyridine (M) nucleobases that expectedly bind to the Hoogsteen face of the 
purine strand of ORN1. One lysine residue was introduced to the amino terminus 
of all PNAs to improve solubility. PNA2 contained three consecutive γ-(R)-
hydroxymethyl units and PNA3 contained a γ-(R)-hydroxymethyl unit at every 
other residue. 19F NMR spectra of ORN3 in the presence of PNAs 1–3 at 25 °C are 
described in Figure 26a. ORN3 alone gave a signal at δ = –62.08 ppm (A). When 
1.0 equivalent of PNAs 1–3 was added, the initial signal was completely replaced 
by a new signal, indicating the formation of PNA/RNA triplex C. When the 
temperature was increased, the chemical shift of these signals nearly followed the 
passive temperature-dependent shift (Figure 26 b–d). The relative peak areas of 
signals C vs. A/B were presented as a function of temperature (Figure 26e). The 
resulting melting profiles followed negative S curves, and the melting temperatures 
of the PNA/RNA triplexes (Tm2) were determined based on the inflection points of 
the curves. As seen in the melting curves and in Table 3, the γ-(R)-hydroxymethyl 
modifications reduced the affinity compared to PNA1 by ∆Tm = –3.7 °C (PNA2) 
and –4.8 °C (PNA3). The thermal melting studies with ORN4/PNA triplexes were 
consistent with these results (Table 3; for the 19F NMR spectra, see the original 
publication III). 
When 2.0 equivalents of PNA1–3 was added to ORN3, an additional signal 
was observed with all PNAs (Figure 26a). This signal was attributed to the 
formation of 2:1 (PNA)2/RNA triplex invasion complex D. The intensity of this 
signal increased when more PNA (3.0 and 4.0 equivalents) was added and the 
intensity of the PNA/RNA triplex signal C decreased respectively (Figure 27 a–c). 
The γ-(R)-hydroxymethyl units reduced the formation of complex D: With PNA1, 
complex C was replaced by complex D after the addition of 3.0 equivalents of 
PNA, whereas 4.0 equivalents of PNA2 were required for the quantitative 
formation of complex D. With PNA3, complexes C and D occurred in 
approximately 1:1 ratio after the addition of 4.0 equivalents of PNA. These 
observations and independent studies with ORN4 (Figure 27d) supported the 
suggestion of (PNA)2/RNA triplex invasion complex.  
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Figure 25.  Thermal melting of the 19F-labeled RNA hairpin models ORN3 and ORN4 followed 
by 19F NMR spectroscopy. Conditions: 50 μmol L–1 of RNA, 10 mmol L–1 sodium 
cacodylate (pH 7.0), 0.1 mol L–1 NaCl in D2O/H2O (1:9, v/v). 
 
40 45 50 55 60 65 70
0.0
0.2
0.4
0.6
0.8
1.0
Model DoseResp
Equation y = A1 + (A2-A1)/(1 + 10^((LOGx0-x)*p))
Plot D E
A1 -0.01503 ± 0.0186 -0.01365 ± 0.01074
A2 0.97309 ± 0.0115 0.97982 ± 0.00598
LOGx0 59.10333 ± 0.23595 57.07132 ± 0.13086
p -0.16066 ± 0.01288 -0.14637 ± 0.00648
Reduced Chi-Sqr 7.1012E-4 1.6854E-4
R-Square(COD) 0.99699 0.9993
Adj. R-Square 0.99609 0.99906
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Figure 26.  19F NMR spectroscopic data of PNA/ORN3 complexes. Conditions: In each 
mixture: 50 μmol L–1 ORN3, 10 mmol L–1 sodium cacodylate (pH 7.0), 0.1 mol L–1 
NaCl in D2O/H2O (1:9, v/v). a) 0–3.0 equiv. of PNA at 25 °C; b–e) 1.0 equiv. of 
PNA. Notes: a) δ(A) = –62.08 ppm; with PNA1, δ(C) = –62.32 ppm and δ(D) = –
62.81 ppm; with PNA2, δ(C) = –62.38 ppm and δ(D) = –62.81 ppm; with PNA3, 
δ(C) = –62.26 ppm and δ(D) = –62.80 ppm. * = single-stranded trace, δ = –62.87 
ppm. 
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Table 3.  19F NMR spectroscopy based thermal melting temperatures [°C] of the heg 
hairpins in the presence of PNAs 1–3. 
RNA 
 
 
Hairpin alone 
Tm1 
PNA1 
Tm2 
PNA2 
Tm2 
PNA3 
Tm2 
ORN3 59.2 ± 0.2 69.7 ± 0.3 66.0 ± 0.1  (–3.7) 64.9 ± 0.2  (–4.8) 
ORN4 56.9 ± 0.1  
 
72.1 ± 0.1 67.9 ± 0.6  (–4.2) 67.9 ± 0.6  (–4.2) 
Conditions: 50 μmol L–1 RNA + 0 (Tm1 values) or 1.0 (Tm2 values) PNA, 10 mmol L–1 sodium 
cacodylate (pH 7.0), 0.1 mol L–1 NaCl in D2O/H2O (1:9, v/v). Notes: Tm1 values are extracted from 
the shift vs. temperature profiles after the subtraction of the passive temperature-dependent shift 
0.0135 ppm °C–1. Tm2 values are extracted from the relative peak areas of the 19F resonance 
signals (Ai/Atot). ∆Tm values given in parentheses are those compared to the Tm values of the 
PNA1/RNA triplex. 
 
It may be worth noting that the purine strand of ORN3 and ORN4 contains a 
symmetric track of eight nucleotides (AGAAAAGA), which may, in principle, 
form a direct antiparallel duplex with PNAs 1–3. In other words, the PNAs could 
also bind to the RNA hairpins through stoichiometric strand invasion. To test the 
favorability of plausible duplex formation, the binding of PNA1 to a single-
stranded RNA model ORN5 was studied (Figure 27e). ORN5 is the purine strand 
of ORN3 and ORN4. ORN5 alone gave a signal at δ = –62.90 ppm (A’). When 
PNA1 was added to ORN5, only one signal at δ = –62.08 ppm was observed. The 
stoichiometry of the binding referred to (PNA)2/RNA complex D’ instead of 
PNA/RNA duplex E’. The absence of the duplex is probably related to the M 
nucleobases that, in their protonated form (pKa = 6.7), are modest Watson–Crick 
binders.25 Thus, it may be concluded that direct strand invasion to the heg hairpin 
models was unlikely. The PNAs bound to ORN3 and ORN4 through Hoogsteen 
base pairing as expected (C), and the (PNA)2/RNA triplex invasion complex D was 
formed after an excess of PNA was added. 
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Figure 27.  19F NMR spectra of  ORN3 + PNA1–3 (2.0–4.0 equivalents) and ORN4 + PNA1 
(0–2.0 equivalents). Conditions: 50 μmol L–1 RNA, 10 mmol L–1 sodium cacodylate 
(pH 7.0), 0.1 mol L–1 NaCl in D2O/H2O (1:9, v/v), 25 °C. 
3.3.2.2 PNA/miR-215 triplexes 
Next, the binding of PNAs to 19F-labeled miR-215 models ORN6 and ORN7 
(Figure 28) was analyzed. MiR-215 is related to cancer development and 
chemoresistance.327,328 Zengeya et al. had previously developed PNA4 (Figure 23) 
for the recognition of a miR-215 model (cf. ORN2 in Figure 23).25 PNA4 contains 
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three M nucleobases25 for the Hoogsteen-face recognition of guanine bases and one 
E nucleobase24,323 for the recognition of the uracil interrupt. According to the ITC 
and UV thermal melting studies of Zengeya et al., PNA4 bound to the miR-215 
model with high affinity (Ka = 1.2×107) and 1:1 stoichiometry at physiologically 
relevant conditions.25 We first wanted to study if the 19F NMR spectroscopic 
analysis would reveal more details of the binding. As with the heg RNA hairpin 
models, the 2’-O-[(4-CF3-triazol-1-yl)methyl]sensors were placed either in the 
middle of the pyrimidine-rich strand (ORN6) or at the opposite site in the purine-
rich strand (ORN7). The 19F NMR spectroscopic measurements were performed 
under the same conditions as with the heg hairpins. Upon heating, both ORN6 and 
ORN7 alone gave the expected A/B coalescence signal (Figure 28 a & b). The 19F 
NMR spectroscopy based melting temperatures (Tm1) were 53.3 °C for ORN6 and 
51.6 °C for ORN7 (Figure 28c). These Tm values were consistent with the Tm 
values obtained by UV spectroscopy: 54.4 °C for ORN2, 54.4 °C for ORN6 and 
52.5 °C for ORN7. As observed with the heg hairpins, the destabilizing effect of 
the 2’-O-[(4-CF3-triazol-1-yl)methyl]sensor was higher in the purine-rich strand 
than in the pyrimidine-rich strand (ORN6 vs. ORN7, ∆Tm = 0 vs. –1.9 °C). 
To study the binding stoichiometry of PNA4 to miR-215, PNA4 was added 
gradually to ORN6. 19F NMR spectra of ORN6 in the presence of 0–2.0 
equivalents of PNA4 at 40 °C are shown in Figure 29a. ORN6 alone gave a signal 
at δ = –61.90 ppm (A). Titration with PNA4 resulted in a new signal very close to 
the original signal, indicating the formation of the PNA4/ORN6 triplex C. 
However, another signal was observed when more than 0.8 equivalents of PNA4 
was added. This signal resulted from the formation of the (PNA4)2/ORN6 triplex 
invasion complex D. According to the relative peak areas of the 19F resonance 
signals, complex C followed 1:1 stoichiometry and complex D 2:1 stoichiometry 
(Figure 29 d). When more than two equivalents of PNA4 (3.0 and 4.0 equivalents) 
were added, no notable change in the chemical shift or intensity of the latter signal 
was observed (see the original publication II).  
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Figure 28.  Thermal melting of the 19F-labeled miR-215 models ORN6 and ORN7 followed by 
19F NMR spectroscopy. Conditions: 50 μmol L–1 of RNA, 10 mmol L–1 sodium 
cacodylate (pH 7.0), 0.1 mol L–1 NaCl in D2O/H2O (1:9, v/v). 
To determine the thermal stabilities of complexes C and D, the 19F NMR spectra 
were recorded at various temperatures. The 19F NMR spectra of ORN6 in the 
presence of 1.0 equivalent of PNA4 at temperatures 40–70 °C are shown in Figure 
30a, and the corresponding relative peak areas of the 19F resonance signals as a 
function of temperature in Figure 30d. Based on these relative peak areas, thermal 
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denaturation profiles and distinct melting temperatures could be determined for 
both complexes: C: Tm2 = 58.9 °C and D: Tm3 = 69.9 °C. It is noteworthy that the 
molar fraction of (PNA4)2/ORN6 complex D increased at elevated temperatures 
and at T > 57.5 °C, D became the predominant complex. Tm3 was determined also 
separately from the melting profile of ORN6 with two equivalents of PNA4 added 
(Figure 30f). Based on this melting curve, Tm3 = 70.3 °C. 
Next, the effect of the γ-(R)-hydroxymethyl modifications on the miR-215 
recognition was studied. The 19F NMR spectra of ORN6 in the presence of 0–2.0 
equivalents of PNA5 and PNA6 at 40 °C are shown in Figure 29. The 19F NMR 
spectra of ORN6 in the presence of 1.0 equivalent of PNA at temperatures 40–65 
°C and the corresponding melting profiles are shown in Figure 30. The 19F NMR 
spectroscopy based melting temperatures are listed in Table 4. PNA5 with three 
consecutive γ-(R)-hydroxymethyl units was first examined. The addition of 1.0 
equivalent of PNA5 resulted in a signal at δ = –61.88 ppm, indicating the 
formation of the PNA5/ORN6 triplex C (Figure 29b). This signal overlapped with 
the initial hairpin signal A at 40 °C, but distinct signals were observed at higher 
temperatures (Figure 30b). The addition of more than 1.0 equivalents of PNA5 
gave rise to broad and undefined resonances, attributed to the unspecific formation 
of the (PNA5)2/ORN6 triplex invasion complex D. According to the relative peak 
areas of the 19F resonance signals, complex C followed 1:1 stoichiometry and 
complex D 2:1 stoichiometry (Figure 29 e). Next, 19F NMR spectroscopic melting 
profiles for C and D were determined (Figure 30 b, e & f). The data showed that 
PNA5 did not reduce the stability of the stoichiometric PNA/RNA triplex C, but 
reduced the stability of the invasion complex D to a great extent (PNA5/ORN6 and 
PNA5/ORN7 triplexes: ∆Tm2 = +0.4 and 0 °C; (PNA5)2/ORN6 invasion complex: 
∆Tm3 = –6.2 °C, Table 4). The Tm3 value of (PNA5)2/ORN7 could not be 
determined because of the wide dispersion of the 19F resonances. The reduced 
stability of complex D along with the wide signal dispersion may be attributed to 
the undefined formation of the invasion complex, or even aggregation. In addition, 
when 1.0 equivalent of PNA5 was added to ORN6, only trace amounts of D were 
observed even at higher temperatures. Hence, PNA5 had an increased selectivity 
for stoichiometric PNA/RNA triplex formation compared to PNA4. 
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Figure 29.  Titration of the miR-215 model ORN6 with PNAs 4–6 followed by 19F NMR 
spectroscopy. Conditions: 50 μmol L–1 ORN6 + PNA4–6 (0–2.0 equivalents), 10 
mmol L–1 sodium cacodylate (pH 7.0), 0.1 mol L–1 NaCl in D2O/H2O (1:9, v/v). 
Notes: a–c) δ(A) = –61.90 ppm, * = single-stranded trace, δ = –62.67 ppm.; a) δ(C) 
= –61.97 ppm and δ(D) = –62.56 ppm; b) δ(C) = –61.88 ppm and δ(D) = –62.20 to 
–62.49 ppm; c) δ(C) = –61.97 ppm and δ(D) = –62.38 ppm. 
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Figure 30.  The thermal unwinding of PNA4–6/miR-215 complexes monitored by 19F NMR 
spectroscopy. Conditions: 50 μmol L–1 ORN6 + PNA4–6 (a–e: 1.0 equivalent; f: 2.0 
equivalents), 10 mmol L–1 sodium cacodylate (pH 7.0), 0.1 mol L–1 NaCl in 
D2O/H2O (1:9, v/v). 
Thereafter, the binding of PNA6 with five γ-(R)-hydroxymethyl units at every 
other position was studied. Interestingly, upon titration of ORN6 with PNA6, the 
triplex invasion complex D was formed without notable accumulation of the 
PNA/RNA triplex C (Figure 29 c & f). However, the 19F NMR spectroscopy based 
Tm3 value of this complex was surprisingly low: Tm3 with ORN6 = 59.3 °C, ∆ Tm3 
= –11.0 °C; Tm3 with ORN7 = 58.0 °C, ∆ Tm3 = –9.8 °C (Figure 30 c & f and 
 
45 50 55 60 65 70 75 80
0.0
0.2
0.4
0.6
0.8
1.0
45 50 55 60 65 70 75 80
0.0
0.2
0.4
0.6
0.8
45 50 55 60 65 70 75 80
0.0
0.2
0.4
0.6
0.8
Results and Discussion 
 73 
Table 4). Hence, PNA6 showed selectivity for the triplex invasion complex D, but 
the stability of the complex was even lower than with PNA5. 
As discussed previously with the heg hairpins, the favorability of direct strand 
invasion to the miR-215 model was evaluated by following the binding of PNA4 to 
a single-stranded model ORN8 (Figure 31). ORN8 is the purine-rich strand of 
ORN7. ORN8 alone gave a signal at δ = –62.76 ppm (A’). The titration of ORN8 
with PNA4 first gave a minor signal at δ = –62.39 ppm, which most likely 
indicated the formation of PNA4/ORN6 duplex E. However, the predominant 
complex at δ = –62.31 ppm followed 2:1 stoichiometry, which referred to the 
formation of (PNA4)2/ORN6 complex D’. Hence, it may be reasonable to conclude 
that the binding of the PNAs to the miR-215 models through direct strand invasion 
was also unlikely, but triplex formation was required for the binding. 
Table 4.  19F NMR spectroscopy based thermal melting temperatures [°C] of the miR-215 
models in the presence of PNAs 4–6. 
RNA 
 
Hairpin alone 
Tm1 
PNA4 
Tm2[a]/Tm3[b] 
PNA5 
Tm2[2]/Tm3[b] 
PNA6 
Tm2[a]/Tm3[b] 
ORN6 
 
53.3 ± 0.4 58.9 ± 0.7[a] 
 
70.3 ± 0.4[b] 
 
59.3 ± 0.6[a]  
(+0.4) 
64.1 ± 0.5[b]  
(–6.2) 
– 
 
59.3 ± 0.5[b]   
(–11.0) 
ORN7 51.6 ± 0.3  
 
57.3 ± 0.6[a] 
 
67.8 ± 0.3[b] 
57.3 ± 0.5[a]   
(0) 
– 
– 
 
58.0 ± 0.4[b]   
(–9.8) 
Conditions: 50 μmol L–1 RNA + 0 (Tm1 values), 1.0 (Tm2 values) or 2.0 (Tm3 values) of PNA, 10 
mmol L–1 sodium cacodylate (pH 7.0), 0.1 mol L–1 NaCl in D2O/H2O (1:9, v/v). Notes: Tm1 values 
are extracted from the shift vs. temperature profiles after the subtraction of the passive 
temperature-dependent shift 0.0135 ppm °C–1. Tm2 and Tm3 values are extracted from the relative 
peak areas of the 19F resonance signals (Ai/Atot). ∆Tm values for PNA5 and PNA6 given in 
parentheses are those compared to the Tm2 and Tm3 values of the PNA4/RNA triplex and 
(PNA4)2/RNA complex. 
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Figure 31.  19F NMR spectroscopy data of PNA4/ORN8 complexes. Conditions: 50 μmol L–1 
ORN8 + PNA (1.0 equivalent), 10 mmol L–1 sodium cacodylate (pH 7.0), 0.1 mol L–
1 NaCl in D2O/H2O (1:9, v/v) at 35 °C. Notes: δ(A’) = –62.76 ppm, δ(E) = –62.39 
ppm, δ(D’) = –62.31 ppm, δ(D) = –62.15 ppm. 
3.3.2.2.1 γ-(S)-guanidinylmethyl-modified TFPNAs  
The experiments with the γ-(R)-hydroxymethyl modified TFPNAs demonstrated 
that γ-chiral modifications affect the binding selectivity between stoichiometric 
PNA/miR-215 triplex and (PNA)2/miR-215 triplex invasion complex. Furthermore, 
the positioning of the chiral units proved important; three consequent γ-(R)-
hydroxymethyl units resulted in the best selectivity for the PNA/miR-215 triplex 
formation. Aiming to enhance the binding properties even more, the effect of γ-(S)-
guanidinylmethyl modifications was next evaluated. The γ-(S)-guanidinylmethyl 
units were introduced into variable positions of the miR-215 recognizing TFPNAs 
(PNAs 7–9, Figure 23). For comparison to the guanidinylmethyl modifications, the 
effect of three simple arginine units at the carboxyl terminus was also evaluated 
(PNA10, Figure 23). For the 19F NMR spectroscopic analysis, ORN6 was selected 
as the target miR-215 model.  
PNA7 and PNA8, containing two and three consecutive γ-(S)-
guanidinylmethyl modifications, showed high selectivity for the stoichiometric 
PNA/RNA triplex formation (Figure 32). When 1.0 equivalent of PNA7 or PNA8 
was added, ORN6 was quite quantitatively replaced by the PNA/ORN6 triplex C 
without notable formation of the (PNA)2/ORN6 complex. When more than 1.0 
equivalent of PNA7 or PNA8 was added, the signal of the PNA/ORN6 triplex was 
replaced by broad and undefined resonances that were very branched at higher 
temperatures. These resonances were attributed to the unspecific formation of the 
(PNA)2/ORN6 complex D, or even aggregation.  Next, 19F NMR spectroscopic 
melting profiles for the PNA7/ORN6 and PNA8/ORN6 triplexes were determined. 
The 19F NMR spectra of ORN6 in the presence of 1.0 equivalent of PNA7 and 
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PNA8 at temperatures 40–70 °C are shown in Figure 33a & b, and the 
corresponding melting profiles in Figure 33d & e. The 19F NMR spectroscopy 
based melting temperature for the PNA7/ORN6 triplex was 60.5 °C, 1.6 °C higher 
compared to the original PNA4/ORN6 triplex. The 19F NMR spectroscopy based 
melting temperature for the PNA8/ORN6 triplex was 62.8 °C, 3.9 °C higher 
compared to the original PNA4/ORN6 triplex. Moreover, in contrast to PNA4, no 
notable formation of the triplex invasion complex was observed even at elevated 
temperatures.  
To study the effect of the spacing between γ-(S)-guanidomethyl units on the 
miR-215 recognition, the binding of PNA9 was examined. PNA9 has three γ-(S)-
guanidomethyl modifications separated by one to three PNA building blocks. In 
earlier studies, the spacing between arginine side chains was demonstrated to be 
important for the cellular uptake of peptides.329 Interestingly, the titration of ORN6 
with PNA9 resulted in a very wide dispersion of 19F resonance signals, indicating 
unspecific formation of the complex C (Figure 32 c). When more than 1.0 
equivalent of PNA9 was added, this signal pattern was replaced by broad and 
undefined resonances, indicating unspecific formation of the complex D. Even if 
the formation of C followed approximately 1:1 stoichiometry and the formation of 
D approximately 2:1 stoichiometry, the wide dispersion of the 19F resonance 
signals suggests unspecific and undefined binding to the ORN6 target. Because of 
the wide dispersion of the signals, the melting temperatures could not be 
determined for C or D.  
Finally, we wanted to study how simple arginine overhang affects the binding 
affinity and Hoogsteen-face selectivity of the TFPNA compared to γ-(S)-
guanidomethyl units. For this purpose, the binding of PNA10 with three arginine 
units at the carboxyl terminus was examined. The titration of ORN6 with PNA10 
showed very similar results compared to PNA4 (Figure 32 d & g). Consequently, 
the arginine units did not affect the Hoogsteen-face selectivity of the binding. 19F 
NMR spectra of ORN6 in the presence of 1.25 equivalents of PNA10 at 
temperatures 40–70 °C are shown in Figure 33c. (1.25 equivalents of PNA10 was 
used to get all of the hairpin A hybridized with PNA10.) The corresponding 
relative peak areas of the 19F resonance signals are plotted as a function of 
temperature in Figure 33f. The melting temperature for complex C was 63.8 °C, 
4.9 °C higher compared to the original PNA4/ORN6 triplex. However, the molar 
fraction of the triplex invasion complex D increased at higher temperatures and D 
became the predominant complex at T > 63 °C. As a matter of fact, the arginine 
overhang proved to stabilize complex D even more than complex C: the melting 
temperature for complex D was 78.0 °C, 7.7 °C higher compared to PNA4 (Table 
5). The 19F NMR spectroscopy based thermal melting temperatures of PNA7–
10/miR-215 complexes are listed in Table 5.   
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Figure 32.  Titration of the miR-215 model ORN6 with PNAs 7–10 followed by 19F NMR 
spectroscopy. Conditions: 50 μmol L–1 ORN6 + PNA7–10 (0–2.0 equivalents), 10 
mmol L–1 sodium cacodylate (pH 7.0), 0.1 mol L–1 NaCl in D2O/H2O (1:9, v/v). 
Notes: a–d) δ(A) = –61.90 ppm, * = single-stranded trace, δ = –62.67 ppm.; a) 
δ(C) = –61.85 ppm and δ(D) = –62.34 to –62.82 ppm; b) δ(C) = –61.83 ppm and 
δ(D) = –62.58 ppm; d) δ(C) = –61.97 ppm and δ(D) = –62.41 ppm. 
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Figure 33. The thermal unwinding of PNA7–10/miR-215 complexes monitored by 19F NMR 
spectroscopy. Conditions: 50 μmol L–1 ORN6 + PNA7–10 (c & f: 1.25 equivalents; 
others: 1.0 equivalent), 10 mmol L–1 sodium cacodylate (pH 7.0), 0.1 mol L–1 NaCl 
in D2O/H2O (1:9, v/v). 
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Table 5.  19F NMR spectroscopy based thermal melting temperatures [°C] of the miR-215 
model ORN6 in the presence of PNAs 7–10. 
ORN6+PNA4 
Tm2[a]/Tm3[b] 
ORN6+PNA7 
Tm2[a]/Tm3[b] 
ORN6+PNA8 
Tm2[a]/Tm3[b] 
ORN6+PNA9 
Tm2[2]/Tm3[b] 
ORN6+PNA10 
Tm2[a]/Tm3[b] 
58.9 ± 0.7[a] 
 
 
70.3 ± 0.4[b] 
60.5 ± 0.6 [a]   
(+1.6) 
 
– 
62.8 ± 0.3 [a]   
(+3.9) 
 
– 
– 
 
 
– 
63.8 ± 0.6 [a]   
(+4.9) 
 
78.0 ± 0.4 [b]  
    (+7.7) 
Conditions: 50 μmol L–1 RNA + 1.0 (Tm2 values) or 2.0 (Tm3 values) of PNA, 10 mmol L–1 sodium 
cacodylate (pH 7.0), 0.1 mol L–1 NaCl in D2O/H2O (1:9, v/v). Notes: Tm2 and Tm3 values are 
extracted from the relative peak areas of the 19F resonance signals (Ai/Atot). ∆Tm values for PNAs 
7–10 given in parentheses are those compared to the Tm2 and Tm3 values of the PNA4/RNA 
triplex and (PNA4)2/RNA complex. 
3.3.3 UV and CD spectroscopic analysis of PNA/RNA 
triplexes 
The UV spectroscopic analysis of the PNA/RNA triplexes was performed by using 
2.0 μmol L–1 solutions of each oligonucleotide in the presence of 0, 1.0 or 2.0 
equivalents of PNA1–10 in a mixture of 10 mmol L–1 sodium cacodylate (pH 7.0) 
and 0.1 mol L–1 NaCl in H2O, detection wavelength λ = 260 nm. The UV thermal 
melting temperatures of the heg hairpins in the presence of PNAs 1–3 are listed in 
Table 6. Because of the 25-fold more diluted RNA concentration, the UV based Tm 
values were lower than the 19F NMR spectroscopy based Tm values. The UV 
melting temperatures confirmed that the γ-(R)-hydroxymethyl modifications 
lowered the thermal stability of the PNA1–3/RNA triplexes, as observed with 19F 
NMR spectroscopy. 
The UV thermal melting temperatures of the miR-215 models in the presence 
of PNAs 4–6 are listed in Table 7 and examples of the UV melting profiles of 
PNA4–6/miR-215 complexes are shown in Figure 34. The UV based melting 
temperatures suggested that the thermal stability of the PNA/miR-215 triplexes 
would be lower with both γ-(R)-hydroxymethyl modified PNAs PNA5 and PNA6. 
However, the 19F NMR spectroscopic analysis showed that the molar fraction of 
the (PNA4)2/miR-215 complex increased at higher temperatures. This fact remains 
hidden in the UV thermal melting profiles. Accordingly, the observed UV melting 
profile with PNA4 is a sum of the melting profiles of both complexes C and D, D 
being thermally more stable than C. Therefore, a falsely high UV based Tm value 
was observed with PNA4. With PNA5, on the other hand, the 19F NMR 
spectroscopic studies showed that practically only PNA/miR-215 triplex is formed 
after the addition of 1.0 equivalent of PNA even at high temperatures. Hence, it 
may be reasonable to confirm that the UV melting profile with PNA5 presents the 
denaturation of PNA/miR-215 triplex only. Likewise, the UV melting profile with 
Results and Discussion 
 79 
PNA6 presents the denaturation of (PNA6)2/miR-215 invasion complex only. The 
UV experiments were also performed with 2.0 equivalents of PNAs 4–6 and using 
280 nm as the detection wavelength (see the original publication III). No 
significant difference from the Tm values in Table 7 was observed. 
Table 6.  UV thermal melting temperatures [°C] of the heg hairpins in the presence of PNAs 
1–3. 
RNA 
 
Hairpin alone 
Tm1 
PNA1 
Tm2 
PNA2 
Tm2 
PNA3 
Tm2 
ORN1 
ORN3 
60.6 ± 0.4 
58.7 ± 0.7 
(–1.9) 
65.6 ± 0.5 
63.9 ± 0.7 
(–1.7) 
62.1 ± 0.4 
60.4 ± 0.6   
(–1.7) 
61.6 ± 0.6 
59.8 ± 0.5   
(–0.8) 
ORN4 57.1 ± 0.7  
(–3.5) 
63.4 ± 0.4 
(–2.2) 
60.2 ± 0.5   
(–1.9) 
58.3 ± 0.8   
(–3.3) 
Conditions: 2.0 μmol L–1 RNA + 0 (Tm1 values) or 1.0 equivalent (Tm2 values) of PNA, 10 mmol L–
1 sodium cacodylate (pH 7.0), 0.1 mol L–1 NaCl in H2O. Notes: ∆Tm values given in parentheses 
are those compared to the Tm values with the unlabeled miR-215 model ORN1. 
Table 7.  UV thermal melting temperatures [°C] of the miR-215 models in the presence of 
PNAs 4–6. 
RNA 
 
Hairpin alone 
Tm1 
PNA4 
Tm2 
PNA5 
Tm2 
PNA6 
Tm2 
ORN2 
ORN6 
54.4 ± 0.6 
54.4 ± 0.7 
(0) 
60.9 ± 0.3 
61.0 ± 0.4 
(+0.1) 
57.2 ± 0.5 
57.0 ± 0.6   
(–0.2) 
54.5 ± 0.5 
54.3 ± 0.7   
(–0.2) 
ORN7 52.5 ± 0.7  
(–1.9) 
59.6 ± 0.1 
(–1.3) 
55.8 ± 0.5   
(–1.4) 
52.4 ± 0.5   
(–2.1) 
Conditions: 2.0 μmol L–1 RNA + 0 (Tm1 values) or 1.0 equivalent (Tm2 values) of PNA, 10 mmol L–
1 sodium cacodylate (pH 7.0), 0.1 mol L–1 NaCl in H2O. Notes: ∆Tm values given in parentheses 
are those compared to the Tm values with the unlabeled miR-215 model ORN2. 
 
The thermal melting of the PNA4–6/miR-215 complexes was also monitored by 
CD spectroscopy using 2.0 μmol L–1 RNA solutions with 1.0 equivalent of PNAs. 
Although the CD spectroscopic data certainly showed differences between 
different PNA/miR-215 complexes (see the original publication III), no convincing 
evidence of different binding modes was observed. To determine the CD based Tm 
values, the ∆A values at a specific wavelength were presented as a function of 
temperature. The Tm value was then determined from the inflection point of the 
resulting curve. The CD based Tm values were consistent with the Tm values 
obtained by UV spectroscopy. 
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Figure 34.  Normalized UV melting profiles of PNA4–6/miR-215 triplexes. Conditions: 2.0 μmol 
L–1 ORN2 (black line) and 2.0 μmol L–1 ORN2 + 1.0 equiv. PNA4 (red line), PNA5 
(blue line), PNA3 (green line), 10 mmol L–1 sodium cacodylate (pH 7.0), 0.1 mol L–
1 NaCl in H2O. 
Next, the thermal melting of the γ-(S)-guanidylmethyl modified PNA7–10/miR-
215 triplexes was monitored by UV spectroscopy. The UV melting profiles of the 
miR-215 model ORN2 with 1.0 equivalent of PNA7–10 are shown in Figure 35 
and the corresponding thermal melting temperatures are listed in Table 8. The 
incorporated γ-(S)-guanidylmethyl units (PNAs 7–9) increased the observed triplex 
melting temperature by 2.0–2.8 °C compared to PNA4. As discussed previously, 
the observed Tm value with PNA4 is probably higher than the Tm value of the 
PNA4/miR-215 triplex, because the observed Tm with PNA4 is a sum of the 
melting profiles of both complexes C and D. With PNA7 and PNA8, on the other 
hand, the 19F NMR spectroscopic measurements showed that practically only 
PNA/miR-215 triplex is formed after the addition of 1.0 equivalent of PNA even at 
high temperatures. Therefore, it may be reasonable to conclude that the observed 
UV melting profiles with PNA7 and PNA8 present the denaturation of the 
PNA/miR-215 triplex only. Interestingly, the UV based Tm value with PNA9 was 
very close to that with PNA8, even if the formation of the PNA9/miR-215 
complexes resulted in a wide dispersion of 19F resonance signals. The 19F NMR 
spectroscopic data proposes that although the UV based Tm was relatively high, the 
formation of the PNA9/miR-215 triplex was unspecific and undefined compared to 
the other PNAs. PNA10, with three arginine units at the carboxyl terminus, gave 
the highest increase in the UV based Tm values, 5.4 °C. However, the 19F NMR 
spectroscopic analysis revealed that PNA10, as well as PNA4, was not very 
selective for PNA/miR-215 triplex formation. After the addition of 1.0 equivalent 
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of PNA10, also (PNA10)2/miR-215 complex was formed, and its molar fraction 
increased at high temperatures. Thus, the real Tm value of the PNA10/miR-215 
triplex may be lower than the observed one. The UV experiments were also 
performed with 2.0 equivalents of PNAs 7–10. 
 
Figure 35.  Normalized UV melting profiles of PNA7–10/miR-215 triplexes. Conditions: 2.0 
μmol L–1 ORN2 + 1.0 equiv. PNA4 (black line), PNA7 (red line), PNA8 (blue line), 
PNA9 (pink line) or PNA10 (green line), 10 mmol L–1 sodium cacodylate (pH 7.0), 
0.1 mol L–1 NaCl in H2O. 
Before the present study, M-modified PNAs had been shown to be highly selective 
for double-stranded RNA over DNA.25 To confirm that the guanidine-
modifications maintain the selectivity for double-helical RNA, the binding of 
PNAs 4 and 7–10 to a miR-215 DNA derivative (ODN17), single-stranded RNA 
(ORN9) and single-stranded DNA (ODN18) was also studied (Figure 36). At least 
in theory, ORN9 and ODN18 are capable of forming a duplex with the TFPNAs 
through A-T and G-M base pairs. The binding was monitored by UV spectroscopy. 
Compared to the PNA/miR-215 triplexes, the observed melting temperatures of the 
PNA/ODN17 triplexes were approximately 20 °C lower and the melting 
temperatures of the PNA/ORN9 duplexes approximately 30 °C lower (see the 
original publication IV). The affinity of the TFPNAs for ODN18 was even weaker. 
As may be expected because of the positive charge of guanidine groups, the γ-(S)-
guanidomethyl and arginine modifications stabilized all the complexes to some 
extent. Nevertheless, the TFPNAs proved to have considerably weaker affinity for 
ODN17, ORN9 and ODN18 compared to miR-215. Thus, the γ-(S)-guanidomethyl 
modified TFPNAs maintained the selectivity for double-stranded RNA. 
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Figure 36.  The sequences of a miR-215 DNA derivative (ODN17) and single-stranded RNA 
(ORN9) and DNA (ODN18) designed to form a duplex with PNAs 4 and 7–10. 
Table 8.  UV thermal melting temperatures [°C] of the miR-215 model ORN2 in the presence 
of PNAs 7–10. 
ORN2+PNA4 
Tm2[a]/Tm3[b] 
ORN2+PNA7 
Tm2[a]/Tm3[b] 
ORN2+PNA8 
Tm2[a]/Tm3[b] 
ORN2+PNA9 
Tm2[2]/Tm3[b] 
ORN2+PNA10 
Tm2[a]/Tm3[b] 
60.9 ± 0.3 [a] 
 
 
62.3 ± 0.3[b] 
62.9 ± 0.3 [a]   
(+2.0) 
 
61.9 ± 0.7 [b] 
 63.7 ± 0.6 [a] 
(+2.8) 
 
63.6 ± 0.8 [b] 
63.3 ± 0.7 [a] 
(+2.4) 
 
66.0 ± 0.4 [b] 
66.5 ± 0.4 [a]   
(+5.4) 
 
68.2 ± 0.6 [b]  
(+1.4) (–1.0) (–0.1) (+2.7) (+1.7) 
Conditions: 2.0 μmol L–1 ORN2 + 0 (Tm1 values), 1.0 (Tm2 values) or 2.0 equivavents (Tm3 values) 
of PNA, 10 mmol L–1 sodium cacodylate (pH 7.0), 0.1 mol L–1 NaCl in H2O. [a] ∆Tm values given in 
parentheses are those compared with the Tm values of ORN2 + PNA1. [b] ∆Tm values given in 
parentheses are those compared with the Tm values of ORN2 + 1.0 equiv. of the corresponding 
PNA.   
3.3.4 Cellular uptake studies of TFPNAs 
To study the influence of the γ-(S)-guanidylmethyl modifications on the cellular 
uptake of PNAs, PNA4, PNA7, PNA8 and PNA10 were selected and labeled at the 
amino terminus with HiLyte Fluor 488 (HF488) dye following a previously 
described protocol (HF488-PNAs, Figure 23).326 The cellular internalization of the 
PNAs to living PC-3 prostate cancer cells was followed by confocal microscopy. 
The cells were incubated with 5 μmol L–1 concentration of the HF488-labeled 
PNAs in OptiMEM (without serum) in the absence of transfection agents for 36–48 
h at 37 °C, 5% CO2. After incubation, the cells were washed with Opti-MEM and 
incubated with Hoechst 33342 to distinguish nuclei. 
At 5 μmol L–1 concentration, PNA7, PNA8 and PNA10 were able to penetrate 
through cell membrane, which was detected as positive fluorescent signal in 
cytoplasm (Figure 37). The fluorescent intensity increased in the order PNA7 < 
PNA8 < PNA10. PNA4, on the other hand, showed no signal at 5 μmol L–1 
concentration. The cellular uptake of PNA4 could be detected after increasing the 
concentration to 10 μmol L–1 (data not shown). Hnedzko et al. previously 
demonstrated that the M nucleobase modification and arginine conjugates both 
enhance the cellular uptake of PNAs.31 Our data shows that the γ-(S)-
guanidylmethyl modifications improve the cellular delivery of PNAs, albeit the 
improvement was lower compared to arginine conjugates (cf. PNA8 with three γ-
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(S)-guanidylmethyl groups vs. PNA10 with three arginine conjugates). The γ-(S)-
guanidylmethyl modification and arginine both bear a guanidine head group that 
has been demonstrated to be the critical component for the more efficient cellular 
uptake of arginine oligomers compared to other polycationic oligomers.330  
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Figure 37.  PNA uptake by PC-3 cells. Cells were incubated with 5 µM PNAs in Opti-MEM for 
36-48 h at 37℃. Cells were washed after incubation, stained with Hoechst 33342 
and detected by confocal microscope (Bar = 50 µm).  
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4 Summary 
Aiming to increase the binding affinity of triplex-forming oligonucleotides (TFOs) 
for DNA duplexes, TFOs were conjugated with neomycin units. The neomycin units 
were conjugated either to the C-5 site (ODN2), C-2’ site (ODN3) or C-4’ site 
(ODN4) of a thymidine residue, and the site within the TFO sequence was also 
varied. The neomycin–TFO conjugates were synthesized on solid support using the 
click chemistry conditions. The effect of the neomycin conjugates on the triplex 
stability was evaluated by UV and CD thermal melting temperature analysis under 
slightly acidic conditions (pH 5.5 and 6.0). The neomycin conjugation site proved to 
be important for the triplex-stabilizing effect: the C-5 conjugates stabilized the 
triplexes remarkably, whereas the C-2’ and C-4’ conjugates caused no effect on the 
triplex stability. The importance of the conjugation site was expected, since the C-5 
site is oriented toward the Watson–Hoogsteen groove, where the binding of neomycin 
takes place. The C-2’ and C-4’ sites, on the other hand, are oriented outward from the 
triple helix.  
At pH 6.0, the C-5 conjugate ODN2 increased the triplex melting temperature Tm3 
by ~ +8 °C (0.1 mol L–1 NaCl) and ~ +4 °C (0.3 mol L–1 NaCl). With two neomycin 
units (ODN7), the triplex-stabilizing effect was doubled (∆Tm3 ≈ +16 °C in 0.1 mol L–
1 NaCl and ∆Tm3 ≈ +13 °C in 0.3 mol L–1 NaCl). The conjugation site within the TFO 
sequence also affected the stabilization (ODN2 and ODN5 vs. ODN6). Compared to 
the triplex-stabilizing influence of discrete neomycin and structurally much simpler 
C-5-(alkyn-1-yl)-modified TFOs,67–70 the stabilization obtained with the neomycin 
conjugates may be smaller than expected. However, the stabilization obtained with 
the bis-neomycin-conjugated ODN7 was remarkable, and the neomycin-conjugated 
TFOs were able to stabilize the triplex also over a Hoogsteen mismatch. Additionally, 
compared to ODN7, a remarkable excess of discrete neomycin is required to stabilize 
triplexes.115,122,133 Although the neomycin–TFO conjugates herein were studied under 
slightly acidic conditions, discrete neomycin has been shown to be still effective at 
pH 8.1.115,125,126,134 Therefore, the binding affinity of these neomycin–TFO conjugates 
at physiological pH could probably be improved by replacing the cytosine residues 
with modified nucleobases, such as 2-aminopyridine derivatives.61–64 In addition, 19F-
labeled target duplexes and 19F NMR spectroscopy were used in this study to provide 
more detailed information on the triplex/duplex/single strand conversion. The 19F 
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NMR spectroscopic analysis revealed the molar fractions of different secondary 
structures (triplex, duplex and single strand) at different temperatures, and an 
indication of locally varying environments in the triplex model was also observed. 
Aiming to recognize variable nucleobases in the pyrimidine strand of double-
helical DNA, 19F-labeled TFO probes were developed. For this purpose, 
phosphoramidite building blocks of CF3-modified sensors F2 and F3 were introduced 
into TFOs by automated DNA synthesizer. The sensors destabilized DNA triplexes, 
but the 19F NMR chemical shifts of the sensors were sensitive to the nucleobase 
content of the target duplex. Unique fingerprints for the nucleobase content were 
observed, particularly with sensor F3 that formed F3*G-X triplets, where X = T, A, C 
or G. Unique 19F resonance signals could be distinguished also from a mixture 
containing all the four target duplexes with variable nucleobase content. 
Because a cytosine-rich triplex model was used (the same model as with the 
neomycin–TFO conjugates), these studies were performed at pH 5.5. As 
discussed previously, the triplex could probably be stabilized at physiological 
pH by replacing the cytosine residues with modified nucleobases. Therefore, the 
principle of 19F-labeled TFO sensors capable of recognizing nucleobase content in 
DNA duplexes proved promising. Compared to fluorescence-based detection methods 
and PCR, the sensitivity of 19F NMR is modest, limiting its applicability to detect 
SNPs. Even if the sensitivity of 19F NMR may be increased by improvements in NMR 
techniques, such as exploiting hyperpolarization,331 the modest sensitivity may 
prevent the use of this kind of 19F-labeled TFO sensors in medical diagnosis. 
However, considering academic interest, these 19F-labeled TFOs stand as another 
proof of the sensitivity of 19F NMR for detecting small changes in the local 
environments of oligonucleotides. This was the first report of 19F-labeled TFOs that 
recognize nucleobase content in the target duplex and the first report of TFOs capable 
of sensing the pyrimidine strand in the target duplex. Additionally, no method for 
distinguishing mismatched Watson–Crick base pairs from each other was reported 
before this study. 
Aiming to increase the binding affinity of triplex-forming peptide nucleic acids 
(TFPNAs) for double-helical RNA hairpins, chiral γ-(R)-hydroxymethyl and γ-(S)-
guanidinylmethyl modifications were introduced to the TFPNAs (PNAs 2, 3 and 5–
9). Additionally, 19F NMR spectroscopy was used to obtain new information on the 
different mechanisms by which TFPNAs bind to double-helical RNA targets, ORN1 
and a miR-215 model ORN2. For this purpose, 19F sensors, previously developed in 
our laboratory, were incorporated to the target RNAs (ORN 3, 4, 6 and 7). The 19F 
NMR spectroscopic analysis revealed detailed information on the stoichiometry and 
transition between alternative binding modes, 1:1 PNA/RNA triple helix and 2:1 
(PNA)2/RNA triplex invasion complex. This information remained hidden in 
conventional UV and CD thermal melting analyses.  
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TFPNAs with two or three consecutive γ-(R)-hydroxymethyl or γ-(S)-
guanidinylmethyl modifications in the middle of the sequence (PNAs 5, 7 and 8) 
reduced the stability of the (PNA)2/miR-215 invasion complex and preferred 
stoichiometric PNA/miR-215 triplex formation. Moreover, the γ-(S)-
guanidinylmethyl-modified PNAs 7 and 8 increased the thermal stability of the 
PNA/miR-215 triplex. The increased Hoogsteen-face selectivity of PNAs 5, 7 and 8 
is likely to originate from the γ-chiral backbone modification that provides favorable 
preorganization for right-handed helical conformation.269,273,332 The increased binding 
affinity is likely to result from the positive charge of the γ-(S)-guanidinylmethyl 
residues at neutral pH. PNA8 with three consecutive γ-(S)-guanidinylmethyl 
modifications showed the best binding affinity and Hoogsteen-face selectivity. 
According to 19F NMR, the triplex melting temperature was increased by ~ 4 °C at pH 
7.0, and the stabilization was observed also by UV spectroscopy. Furthermore, γ-(S)-
guanidinylmethyl modifications enhanced the cellular uptake of TFPNAs. It should 
be noted that relatively high concentrations (50 μmol L–1) were used in the 19F NMR 
measurements, and the molar fractions of (PNA)2/RNA triplex invasion complexes 
may be less prominent at lower concentrations. However, different binding modes are 
still likely to be present also at lower concentrations. For the potential therapeutic 
applications in the future, it is crucial to confirm the selective binding of TFPNAs and 
to reveal the equilibria between different binding modes and how they are affected by 
modifications. 
  88 
5 Experimental 
5.1 General 
The syntheses and characterization of novel compounds are described in the original 
publications. The novel compounds were characterized by 1H NMR, 13C NMR, 31P 
NMR, 19F NMR and HRMS when applicable. The optical purity of compounds 35 
and 40 was confirmed by chiral HPLC analysis using an analytical chiral Lux 
Cellulose (250 × 5 mm, 5μm) column, isocratic elution with 25% (compound 35) or 
70% (compound 40) iPrOH in hexane, flow rate 1.0 mL min–1 and UV detection at 
260 nm. For reference, small quantities of the S-isomers of compounds 35 and 40 
were synthesized. The chiral HPLC profiles are provided in the original publications 
II and IV. 
5.2 Oligonucleotide synthesis 
The oligonucleotides were synthesized with an Applied Biosystems 3400 DNA/RNA 
synthesizer using standard protocols. More details on the oligonucleotide synthesis 
are provided in the Results and Discussion and in the original publications. 
Oligonucleotides were purified by RP-HPLC using a semipreparative column (C-18, 
250 mm x 10 mm, 5 μm) with a gradient elution, typically from 0 to 40–60% 
acetonitrile in 0.1 mol L–1 aqueous triethylammonium acetate over 25 min, flow rate 
3.0 mLmin–1, UV detection wavelength 260 nm. The homogeneity of the purified 
oligonucleotides was confirmed by RP-HPLC using an analytical column (C-18, 250 
mm x 5 mm, 5 μm), flow rate 1.0 mLmin–1, elution conditions and detection 
wavelength the same as during purification. The authenticity of the oligonucleotides 
was verified by electrospray ionization time-of-flight mass spectrometry (ESI-TOF 
MS). 
5.3 PNA synthesis 
PNAs were synthesized on a 10 μmol scale on a Rink amide-derived Chem Matrix 
resin by Applied Biosystems 433A peptide synthesizer. In the PNA synthesis, the 
modified PNA monomers 1–5 and commercially available Fmoc-PNA-T-OH and 
amino acid building blocks (Boc-Lys(Fmoc)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-
Experimental 
 89 
Lys(Fmoc)-OH) were incorporated into the PNA sequences using Fmoc/t-Bu peptide 
synthesis cycle. Benzotriazol-1-yl-oxytripyrrolidinophosphonium 
hexafluorophosphate (PyBOP) was used as coupling reagent. For each coupling, PNA 
monomer/amino acid (50 μmol, 0.25 mol L-1 solution in NMP), PyBOP (5 equiv), 
DIEA (10 equiv) and a 30 min coupling time at rt were used. The coupling was 
followed by a capping step with an acetic anhydride treatment (Ac2O, Py, NMP, 
1:25:25, v/v/v, 1 min at rt. For the Fmoc deprotection, 20% piperidine in NMP was 
used (7 min at rt). Solid-supported PNAs were released with a mixture of anisole and 
TFA (1:10, v/v, 2 h at rt), precipitated in cold diethyl ether, dissolved in a 0.1% 
aqueous solution of TFA, and purified by RP HPLC. The product fractions were 
lyophilized to dryness to give the desired homogenized PNAs as white powders. The 
homogeneity of the products was confirmed by RP HPLC, and the authenticity was 
verified by MS (ESI-TOF). Yields of the isolated products were determined from the 
UV absorbance at λ = 260 nm. 
5.3.1 Synthesis of guanidine-modified PNAs 7–9 and HF488-
PNAs 7–9 
After automated PNA synthesis, the γ-(R)-azidomethyl groups of PNAs 7–9 (N3) 
were reduced into γ-(S)-aminomethyl groups and then guanidinylated on solid 
support. For the reduction step, the resin was suspended in a mixture of water and 
dioxane (1:4, v/v) and a solution of 1 mol L-1 Me3P in toluene (24 equiv/amino group) 
was added under nitrogen atmosphere. The suspension was shaken for 2 h at room 
temperature, after which the resin was filtered and washed with DMF and CH2Cl2. 
For the guanidinylation step, the resin was suspended in dry THF and 1,3-di-Boc-2-
(trifluoromethylsulfonyl)guanidine (10 equiv/amino group) and triethylamine (50 
equiv/amino group) were added. Because the guanidinylation required highly basic 
conditions, the lysine at the amino terminus of the PNA was protected with Boc 
instead of Fmoc. The suspension was shaken overnight at room temperature. The 
guanidinylation step turned out to be sluggish, and the treatment was repeated 8 times 
to get all the amino groups guanidinylated. Thereafter, the resin was filtered, washed 
with DMF and CH2Cl2 and PNAs were released from the solid support as described 
previously. 
When synthesizing γ-(S)-guanidinylmethyl modified HF488-PNAs 7–9, the 
synthesis was continued after the guanidinylation step. Therefore, the lysine at the 
amino terminus of the PNA had to be protected with Fmoc instead of Boc. 
Consequently, less basic conditions (1 equivalent triethylamine/amino group) were 
used and the treatment was repeated three times overnight. Although the 
guanidinylation was not fully complete after this treatment, the final products could 
be purified effortlessly by RP HPLC after attaching the AEEA spacers and the HF488 
label.  
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5.4 UV and CD thermal melting studies 
The UV melting curves (absorbance vs. temperature) were recorded at 260 or 295 nm 
on a Perkin Elmer Lambda 35 UV-vis spectrometer equipped with a multiple cell 
holder and a Peltier temperature controller. The Tm values were determined as the 
local maximum (260 nm) or minimum (295 nm) of the first derivative of the melting 
curve. The CD spectra were recorded on an Applied Photophysics Chirascan 
spectropolarimeter. With both instruments, an internal thermometer was used to 
confirm the accurate target temperature. The detailed measurement conditions are 
described in the Results and Discussion and in the original publications. 
5.5 19F NMR studies 
The 19F NMR spectra were recorded at a frequency of 470.6 MHz on a Bruker 
Avance 500 MHz spectrometer (publications I, II and IV) or Bruker Avance III HD 
600 MHz spectrometer equipped with a cryogenic probe (publication III). The 
cryogenic probe increases the sensitivity ca. tenfold compared to conventional probes 
that work at ambient temperature. Typical experimental parameters were as follows: 
19F excitation pulse 4.0 μs, acquisition time 1.17 s, prescan delay 6.0 μs, relaxation 
delay 0.8 s and the typical number of scans 2048. The parameters were optimized to 
obtain the signals with the longest relaxation rate. The temperature ramps were 
recorded automatically using a macro command and a 20 min equilibration time for 
each temperature. The sample temperatures were calibrated using known chemical 
shifts of ethylene glycol at different temperatures. The detailed measurement 
conditions are described in the Results and Discussion and in the original 
publications. 
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